The female reproductive system is strongly influenced by nutrition and energy balance. It is well known that food restriction or energy depletion can induce suppression of reproductive processes, while overnutrition is associated with reproductive dysfunction. However, the intricate mechanisms through which nutritional inputs and metabolic health are integrated into the coordination of reproduction are still being defined. In this review, we describe evidence for essential contributions by hormones that are responsive to food intake or fuel stores. Key metabolic hormones—including insulin, the incretins (glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1), growth hormone, ghrelin, leptin, and adiponectin—signal throughout the hypothalamic–pituitary–gonadal axis to support or suppress reproduction. We synthesize current knowledge on how these multifaceted hormones interact with the brain, pituitary, and ovaries to regulate functioning of the female reproductive system, incorporating in vitro and in vivo data from animal models and humans. Metabolic hormones are involved in orchestrating reproductive processes in healthy states, but some also play a significant role in the pathophysiology or treatment strategies of female reproductive disorders. Further understanding of the complex interrelationships between metabolic health and female reproductive function has important implications for improving women’s health overall.

Reproduction is an energetically expensive process, and the energetic costs are largely borne by the females of many species. The mammalian female reproductive system is responsible for producing female gametes, facilitating their fertilization with sperm, supporting embryonic-fetal growth and development, and enabling the birth and nourishment of the offspring. These complex processes require a high level of communication between various organ systems, and so reproduction is under tight control of centrally produced hormones released by the hypothalamus and pituitary, as well as signaling factors produced by the placenta, developing embryo, and tissues of the reproductive system. Considering the high energetic requirements of gamete production, gestation, and lactation, it is clear that levels of food and energy stores are additional pieces of information that must be incorporated into the control of reproductive processes. Therefore, hormones that are classically defined by their metabolic roles are also critically important for regulating reproduction, including those which relay acute changes in ingestion and nutrient levels (e.g., insulin, the incretins, growth hormone, and ghrelin), as well as hormones that communicate stored metabolic fuel levels (e.g., leptin and adiponectin).

Strong links between nutritional status and female reproductive function are evident throughout the animal kingdom. Vertebrate orexigenic and anorectic neuropeptides that are classified based on their effects on appetite also modify levels of gonadotropin hormones in the reproductive axis [1]. Many bird species breed seasonally, which restricts reproductive activity to periods when local food supply is optimal for supporting increased metabolic demands [2,3]. Food availability affects fecundity and the timing of sexual maturity in fishes, and female iteroparous fishes may skip a spawning season if nutrient levels are insufficient [4,5]. There are also insect and nematode species that can enter diapause states to reversibly suspend development and reproduction under unfavourable conditions. Entry into or recovery from diapause in these invertebrate organisms is orchestrated in part by evolutionarily conserved signaling systems that communicate nutritional status [6,7]. Mammals exhibit patterns of sexual dimorphism that are consistent with the concept that females are better suited for withstanding periods of food scarcity, which would increase chances of reproductive success in nutritionally-fluctuating environments [1]. For instance, in contrast with males, female mammals tend to favor energy storage over the capacity for rapid fuel mobilization, and are more prone to accumulate adipose mass in subcutaneous depots [8–10].

In humans, the relationship between nutrient levels and female reproductive health is most obvious when an imbalance in nutrient and energy levels pushes functioning of the reproductive system off-kilter. This is exemplified by physiological responses to food restriction and excessive energy expenditure, or conversely by the reproductive system disorders that are linked to overnutrition.

Inadequate energy and reproductive dysfunction

Energy deficiency caused by stress, low food intake, or strenuous exercise can result in a suppression of neuroendocrine signals that allow normal menstruation and ovulation. This deregulation is signified by a loss or alteration of gonadotropin hormone pulsatility, and leads to ovarian responses such as decreased estradiol production [11–13]. Low energy availability can thereby cause primary amenorrhea, a delay in menarche, or secondary amenorrhea, a temporary halt in natural menstrual cycling [14]. Studies in human populations exemplary of a negative energy balance have shed light on aberrant menstrual patterns. Ballet dancers [15,16] and athletes [17,18] engaged in high physical activity may have a delayed pubertal onset. Additionally, disordered eating, excessive exercise, or lifestyle stressors can cause menses loss in erstwhile normal-ovulatory women [19–22]. Temporary food deprivation or fasting can also induce a drop in gonadotropin levels and rise in cortisol [23–27]. Furthermore, women in poverty-stricken and/or strenuous labor-demanding societies experience increased risks of adult amenorrhea and lower birth rates [28–32].

Importantly, the ready availability of energy or metabolic fuels is more critical to reproductive fitness than adiposity per se. Food-deprived or over-exercised females can adjust food intake or activity to restore normal ovarian cyclicity and gonadotropin pulsatility before changes in adiposity or weight are evident [33–36]. Similarly, short fasting intervals halt ovarian cycles in Syrian hamsters without affecting adiposity, by reducing free fatty acid oxidation [37,38]. Maintaining glucose availability also preserves reproductive function in rodents and primates [39–43].

Amenorrhea and subfertility are not merely disorders of the reproductive system, but instead have broad physiological impacts. Just as a reduction in estrogen levels in postmenopausal women increases risks of cardiovascular disease [44], bone frailty [45], and neuropsychiatric disorders [46], a premenopausal estrogen deficiency caused by amenorrhea leads to compromised cardiovascular, skeletal, and mental health [47–51]. Thus, reproductive system responses to nutritional cues have far-reaching effects.

Excess energy and reproductive dysfunction

Undernutrition can suppress signals that allow reproduction, but chronic overnutrition is also associated with reproductive dysfunction. The recent prevalence of ultra-processed and low-satiating foods, combined with a more sedentary lifestyle, has led to a surplus of calories in everyday life [52–56]. Animal studies have shown that high-energy, high-fat diets interfere with reproductive function independent of obesity [57–60]. Additionally, obesity and a high body mass index are themselves associated with precocious menarche [61–65], menstrual cycle irregularities [66–69], infertility [70–73], miscarriage [74–76], and fetal abnormalities [77–82]. Diets that are high in refined carbohydrate also predict an earlier age of menopause [83,84].

Energy overload and reproductive dysfunction are also closely associated in the context of polycystic ovary syndrome (PCOS), the most prevalent female reproductive disorder [85,86]. The diagnostic features of PCOS include hyperandrogenism, menstrual cycle irregularities, and an accumulation of fluid-filled cysts in the ovaries [87,88]. However, PCOS has heterogeneous symptoms that often include obesity, elevated insulin, and/or a diminished capacity for glucose disposal [89,90]. These metabolic characteristics exacerbate the reproductive features of PCOS through such means as heightening testosterone levels [91–95]. Hypercaloric, high-fat diets also potentiate the traits of PCOS [96–98]. Women with PCOS tend to have difficulty conceiving, as well as a greater risk of pregnancy complications such as gestational diabetes, preeclampsia, or miscarriage [99–109]. PCOS is also associated with increased incidence of Type 2 diabetes [110–112], hypertension [110,113–117], high cholesterol [118–120], stroke [121,122], and cancer [123–126].

Weight loss [127–129], exercise [129–134], and bariatric surgery to limit food intake [135–140] are useful clinical tools for treating some aspects of the reproductive dysfunction associated with energy surplus. Lifestyle approaches such as balanced diet selections favoring whole grains, vegetables, fish, and unsaturated fats rather than saturated or trans fats are associated with increased fertility, improvements to PCOS symptoms, and beneficial impacts on other aspects of gynecologic health [141–144]. However, there is a lack of widespread awareness that diet has important implications for reproductive health (beyond effects on weight loss or perinatal health), and this is compounded by barriers preventing equal access to healthy diet options [143].

Effective management of nutritional and energy inputs is imperative for maintaining reproductive health. Nutrition and energy balance affect many aspects of reproductive health, including the menstrual cycle, fertility, pregnancy, fetal health, and age-related reproductive decline. This is due in part to the hormones that interpret food intake and fuel stores, which cooperate with cellular nutrient sensors to trigger the appropriate physiological responses for systemic energy homeostasis. These metabolic hormones engender changes across the reproductive axis, from the hypothalamus and pituitary to peripheral tissues of the female reproductive system (Figure 1).

Metabolic hormones act as key intermediaries in linking nutrient and energy status to female reproductive function

Figure 1
Metabolic hormones act as key intermediaries in linking nutrient and energy status to female reproductive function

Energetic deficits generally decrease levels of insulin, the incretin hormones (GIP and GLP-1), and leptin while also raising growth hormone, ghrelin, and adiponectin. Conversely, food ingestion and/or a chronic energy surplus causes the opposite shift in circulating levels of these hormones. Metabolic hormones act directly within the hypothalamus, pituitary, and ovaries to modulate reproductive processes. Their effects are thereby integrated into the reproductive axis, in which the hypothalamus and anterior pituitary communicate with the female reproductive system through the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH), while the ovaries in turn provide feedback via steroid hormones and other signaling factors.

Figure 1
Metabolic hormones act as key intermediaries in linking nutrient and energy status to female reproductive function

Energetic deficits generally decrease levels of insulin, the incretin hormones (GIP and GLP-1), and leptin while also raising growth hormone, ghrelin, and adiponectin. Conversely, food ingestion and/or a chronic energy surplus causes the opposite shift in circulating levels of these hormones. Metabolic hormones act directly within the hypothalamus, pituitary, and ovaries to modulate reproductive processes. Their effects are thereby integrated into the reproductive axis, in which the hypothalamus and anterior pituitary communicate with the female reproductive system through the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH), while the ovaries in turn provide feedback via steroid hormones and other signaling factors.

Close modal

The hypothalamus and anterior pituitary

The hypothalamic–pituitary–gonadal (HPG) axis comprises a system wherein the hypothalamus and anterior pituitary cooperate to centrally control gonadal maturity and function. Gonadotropin-releasing hormone (GnRH) is a tropic hormone secreted by a small subset of hypothalamic neurons in response to a suite of peripheral signals and neuronal messengers, including inputs from kisspeptin (Kiss1) neurons, astrocytes, γ-aminobutyric acid (GABA) neurons and pro-opiomelanocortin (POMC) neurons [145,146]. Pulses of GnRH released into portal circulation range in frequency from pulsatile to surge mode, depending on sex, age, and menstrual cycle phase [147–150]. Although the HPG axis is first established in utero, it is largely silenced until the initiation of nocturnal GnRH pulses during the onset of puberty [151,152]. Kisspeptin signaling is a key player in reactivating the HPG axis and initiating the pulsatile hypothalamic GnRH secretion required for sexual maturity and reproductive function [153–157]. Thereafter, rhythmic changes in frequency and amplitude of GnRH pulses are integral for controlling the differential secretion pattern of the two gonadotropin hormones, together with regulatory input by other systemic and paracrine factors.

Gonadotroph cells of the anterior pituitary produce the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [158,159]. GnRH signaling induces differential expression of genes encoding LHβ and FSHβ subunits, in addition to regulating LH and FSH exocytosis [160]. In turn, FSH and LH exert controls over ovarian function, including steroidogenesis, follicular development, and ovulation. Together, forward-acting and feed-back regulatory loops facilitate a dynamic, nuanced reproductive axis that can be adjusted at multiple levels in response to internal and external conditions [161]. For instance, crucial information related to nutritional status and energy balance is incorporated into the reproductive axis via metabolic hormones exerting effects on GnRH production and release, gonadotropin secretion, and ovarian functions.

The ovaries

Oogenesis, folliculogenesis, and the production of steroid hormones and other signaling factors are tightly regulated ovarian processes that are responsive to inputs such as metabolic hormone signaling. Oogenesis begins early in embryonic development with primordial germ cells that divide by mitosis to form oogonia, which may continue to mitotically divide, undergo programmed cell death, or enter into meiosis as primary oocytes [162]. Primary oocytes do not complete meiosis, but are instead arrested and individually surrounded by a sheath of granulosa cells in structures called primordial follicles [163,164]. Female humans are born with approximately one million non-atretic primordial follicles, which constitute the initial ‘ovarian reserve’ [165].

After birth, primordial follicles are continuously recruited into a pool of growing follicles that routinely undergo atresia, or apoptosis-mediated degeneration [166–169]. Since primordial follicles lack an independent blood supply, the early stages of folliculogenesis are under limited endocrine regulation; the transition from primordial to primary follicle is largely controlled by intra-ovarian paracrine signaling [170]. Granulosa cells of a primary follicle begin to express FSH receptors, and FSH is involved in stimulating the progression into a secondary follicle [171–173]. Theca cells enveloping the follicle develop LH receptors late in the secondary follicle stage [174], and the thecal layer becomes increasingly vascularized as the antral follicle develops [175]. Preantral stages of folliculogenesis continuously generate a pool of developing follicles which almost all default to atresia [170,176]. However, with the stimulation by gonadotropins that occurs after puberty, a very small cohort of ∼10 antral follicles is recruited each month for further maturation [176].

In response to FSH and LH, granulosa cells and theca cells cooperatively participate in steroidogenesis to produce androgens, estrogens, and progesterone [177,178]. The dominant follicle heightens production of estradiol and other signaling factors that act locally as well as centrally suppressing FSH production; this ultimately pushes the non-dominant follicles to atresia, since they have fewer FSH receptors and are outcompeted for FSH, a survival factor that inhibits follicular atresia [179,180]. The oocyte resumes meiosis as the dominant antral follicle continues to mature. Eventually, sustained high estradiol levels triggers a surge in centrally produced LH and FSH, driving follicle rupture and ovulation of the oocyte surrounded by supporting granulosa cells called cumulus cells [181,182]. Meanwhile, the residual follicle somatic cells differentiate into a temporary endocrine gland called the corpus luteum [183,184]. Ovulation occurs monthly in healthy females until approximately 50–55 years of age, when the ovarian reserve is exhausted [185–188]. The resultant drop in levels of follicle-produced hormones and signaling factors ripples through the HPG feedback system, leading to fluctuations in GnRH pulses and high circulating LH and FSH before gonadotropin levels eventually decline after menopause [189,190].

Cellular nutrient sensors

Cellular nutrient sensors are expressed in the hypothalamus, pituitary and ovaries, where they interpret local quantities of metabolites or energy-carrying molecules and interact with different cellular players to govern functioning of the female reproductive system. As comprehensively described in recent review articles [191–195], these nutrient sensors exert direct and indirect effects on female reproductive function. For instance, mechanistic target of rapamycin (mTOR), a protein kinase that promotes anabolic processes in response to increased amino acids and growth signals, is involved in regulating primordial follicle activation and granulosa cell proliferation, among other metabolically important functions. Similarly, AMP-activated protein kinase (AMPK), a nutrient sensor activated by a drop in cellular energy, plays a role in maintaining organismal energy homeostasis that extends to influencing pubertal timing and oocyte maturation.

Along with their own nutrient-sensing functions, cellular nutrient sensors are integral signaling intermediaries by which metabolic hormones probably direct some of their effects on reproductive physiology. For example, adiponectin can induce mTOR inhibition and AMPK activation [196], whereas the insulin signaling cascade is capable of promoting mTOR activity and inhibiting AMPK [197,198]. However, delineating these relationships in the context of reproductive functions is complicated by tissue-specific and context-dependent interactions. For instance, the adiposity signal leptin inhibits hypothalamic AMPK but activates skeletal muscle AMPK, whereas fasting-induced ghrelin activates AMPK in the hypothalamus while inhibiting AMPK in adipose tissue and liver [199]; it is unclear how these signaling hubs interact elsewhere, such as in ovarian cells. Intricate, bidirectional cross-talk between signaling pathways of cellular nutrient sensors and metabolic hormones further exacerbates the difficulties of defining their individual roles in regulating reproductive processes.

Insulin is best known for maintaining blood glucose levels, but it also regulates carbohydrate, lipid and protein metabolism, appetite, cell division, cell growth, and lifespan. A peptide hormone predominantly produced by β cells of the pancreatic Islets of Langerhans, insulin is secreted in response to the glucose, fatty acids, and amino acids that become elevated in circulation due to food intake. However, insulin levels are under multifactorial control, and autonomic nervous system innervation as well as other hormones (such as growth hormone and glucagon-like peptide 1) also affect insulin production and secretion; circulating levels are further controlled at the level of its clearance [200–203]. Insulin was discovered in 1921-22 with the extraction and purification of a pancreatic substance that could effectively lower blood glucose levels in patients with Type 1 diabetes [204,205]. It had a transformative impact on the treatment of diabetes, establishing its fundamental metabolic role.

Although insulin was discovered in mammals, it is now well known that insulin-like peptides and their highly conserved signaling cascades regulate metabolism, development, and aging across the animal kingdom. Ligand binding to insulin/insulin-like growth factor 1 (IGF-1) tyrosine kinase receptors leads to the activation of downstream signaling effectors, including phosphatidylinositol 3-kinase (PI3K, whose activities are counteracted by phospholipid phosphatases like PTEN) and the serine/threonine kinase AKT. The PI3K/AKT signaling pathway is associated with promoting glucose uptake and storage, suppressing hepatic glucose release, stimulating lipogenesis, and inhibiting mobilization of stored lipids [197,206]. Another major branch of insulin/IGF-1 signaling is transduced via the mitogen-activated protein kinase (MAPK)/ERK cascade, which is primarily involved in regulating growth and cell proliferation [197,206]. These signaling cascades also interact with other nutrient sensor mechanisms, through such means as activating mTOR and inactivating AMPK [197].

Lowering insulin below a critical threshold causes diabetes, but elevated insulin is also associated with detrimental changes. Insulin hypersecretion is a driving factor for insulin resistance, obesity, and other aspects of metabolic dysfunction [207]. Notably, in the ‘insulin resistant’ state that is defined by impaired insulin-induced glucose disposal, only a subset of insulin-regulated processes have diminished responses to insulin; tissues such as ovaries and the pituitary might remain mostly insulin-responsive [207–209]. The elevation in circulating insulin that often accompanies insulin resistance could thereby exacerbate insulin signaling responses in the female reproductive system.

Insulin and the female reproductive system

Insulin and the insulin signaling pathway are important regulators of reproduction, and there can be detrimental outcomes of either insufficient or excess levels. Manipulations such as brain-wide deletion of insulin receptors (InsR) suppress GnRH release in mice, leading to impaired follicle maturation and reduced fertility [210]. On the other hand, high insulin levels induced by high-fat feeding are accompanied by fewer estrous cycles, fewer preantral and antral follicles, and smaller litters; exogenous insulin also causes a reduction in murine oocyte yield and quality [198,211,212]. In humans, an infusion of insulin and lipids acutely suppresses FSH and LH levels [213]. Elevated insulin at birth and during childhood is associated with earlier puberty [214], and insulin levels in reproductive-aged women are negatively correlated with levels of anti-müllerian hormone (AMH), an ovary-produced hormone that signifies ovarian reserve [215].

Insulin receptors are expressed widely in the brain [216,217], including in GnRH neurons, astrocytes, and Kiss1 neurons [218–221]. Astrocytes are implicated in the insulin-mediated regulation of GnRH release [222], and InsR ablation in astrocytes results in altered ovarian cycling, impaired oocyte maturation, hypogonadism, and subfertility [223]. Cultured GnRH cell-lines also contain InsRs [224], and insulin stimulates GnRH expression and promotes its effects on gonadotropin secretion in vitro [225–227]. GnRH-specific InsR knockout mice are protected from obesity-associated infertility, with GnRH pulses that are comparable to lean control mice [228]. InsR knockout in the pituitary [211] or ovarian theca cells [229] also protects female mice from high-fat diet-induced infertility, showing that elevated insulin acts across multiple systems to impair reproductive function under conditions of nutrient surplus.

Insulin has direct ovarian effects on metabolism, steroidogenesis, and folliculogenesis. The InsR is expressed in oocytes, granulosa cells, and theca cells of rodent, bovine, and human ovaries [230–234]. Insulin signaling is crucial for supporting glucose uptake and glycolysis in the ovary, to provide energy for folliculogenesis [235,236]. Insulin also plays an important role in steroidogenesis, by cooperating with LH to stimulate androgen production in theca cells [91,237,238]. It promotes the primordial to primary follicle transition in a rat ovarian organ culture system [239], and supra-physiological levels of insulin stimulate bovine oocyte cleavage, maturation and meiotic progression in vitro [240,241]. In vivo, oocyte-specific InsR deletion appears to have minimal impacts on fertility in mice [242]. Similarly, InsR ablation in murine granulosa or theca cells can lead to altered steroidogenesis and gene expression changes without overt effects on gross ovarian morphology or fertility under standard dietary conditions [229,243]. However, insulin and IGF-1 are closely related and can bind to each other's receptors or hybrid insulin-IGF-1 receptors with varying affinities [244]. Notably, double knockout of InsR and IGF-1 receptors in granulosa cells causes significant infertility, by impairing oocyte development and ovulation to a greater degree than knockout of either receptor alone [243]. IGF peptides, binding proteins, and receptors are expressed in human follicles [245], and IGF-1 is itself important for regulating follicular growth and survival as well as FSH-induced processes such as estradiol production, granulosa cell differentiation, and ovulation [246–252].

Downstream insulin/IGF-1 signaling components are established players in maintaining ovarian function and balance in folliculogenesis. For instance, overexpression of PI3K in the oocytes of neonatal mice increases follicular numbers, reduces apoptosis, and triggers an anovulatory state due to an excess of overgrown follicles [253]. Similarly, oocyte-specific removal of the counter-regulatory PTEN causes premature activation and exhaustion of the quiescent follicular pool [254]. Akt is widely expressed in ovarian stromal and germ cells in humans [255] and rodents [256], and Akt-deficient mice have delayed puberty onset, reduced fertility, altered steroid hormone levels, and a predisposition for PCOS-like phenotypes [257,258]. PI3K/AKT signaling maintains the primordial follicle pool in part by phosphorylating and inactivating the FOXO3 transcription factor, which otherwise suppresses primordial follicle activation when active [259]. Mice with constitutively activated oocyte FOXO3 maintain follicle numbers, gonadotropin levels, and youthful gene expression profiles with advancing age [260].

Abnormal insulin levels—relatively common with metabolic disorders—are linked to impaired reproductive health. For instance, women with Type 1 diabetes (typically treated with exogenous insulin) are more likely to exhibit ovarian dysfunction, and those taking a higher daily dose of insulin have an increased chance of earlier menopause [261,262]. An early diagnosis of Type 2 diabetes, which is closely tied to obesity and high endogenous insulin, is also predictive of earlier menopause [261,263–265]. Elevated insulin is a cardinal feature of PCOS that aggravates its reproductive pathophysiology, by augmenting testosterone production and bioavailability as well as inhibiting follicular growth and maturation [88,89]. Therefore, while insulin signaling is essential for metabolic and reproductive functions, preventing insulin excess could have promising therapeutic potential [207].

Incretins are metabolically active gut hormones released promptly after food consumption. Seminal work in the 1960's pointed to the existence of factors that heighten insulin levels in response to ingestion [266–268]. Glucose-dependent insulinotropic polypeptide (GIP) was isolated in 1971 [269] and shown to potentiate insulin levels in response to intestinal absorption of nutrients such as glucose [270]. Glucagon-like peptide 1 (GLP-1) was later identified as another potent insulinotropic hormone [271]. GLP-1 also promotes the proliferation of β-cells [272,273] and prevents their apoptosis [274]. In addition, GLP-1 contributes towards maintaining glucose homeostasis by lowering food intake, glucagon secretion, and endogenous glucose production [275–277].

GIP and GLP-1 are produced by intestinal enteroendocrine cells. GIP is secreted by the K-cells of the small intestine in response to the ingestion and absorption of glucose, lipids, and high levels of amino acids [270,278–281]. GLP-1 is secreted by the large intestine and the L-cells of the small intestine [282,283]. GLP-1 is the post-translational cleavage product of the proglucagon gene, and is stimulated by monosaccharides such as glucose, fructose, and galactose [284,285], as well as dietary lipids [286,287] and amino acids [288–291]. Upon their release into circulation, the incretins bind to their respective G-coupled receptors (GIPR and GLP-1R), which in pancreatic β cells stimulate insulin exocytosis by inducing a rise in intracellular cAMP and calcium levels [292,293]. The insulinotropic effects of incretins are largely mediated by β cells, but incretin receptors have a broad distribution across many tissues, including in the hypothalamus [292–294]. GLP-1 produced within the brain also appears to contribute to its central effects [292,295].

Despite higher circulating levels, the insulinotropic effects of GIP dwarf in comparison to GLP-1, which is widely popularized as a therapeutic target. GLP-1 can normalize blood glucose levels in Type 2 diabetes patients [296] and promote weight loss [297]. However, GIP and GLP-1 are enzymatically inactivated after secretion, and the rapid degradation of GLP-1 limits its therapeutic potential [298]. Efforts have now shifted to using GLP-1 receptor agonists [299–301] or dual GIP- and GlP-1- receptor agonists [300,302,303]. Incretin-based therapy has expanded to target fatty liver disease [304,305], kidney disease [306], neurodegenerative diseases [307,308] and reproductive disorders such as PCOS [309,310].

Incretin hormones and the female reproductive system

The incretin hormones might elicit indirect, insulin-mediated impacts on female reproductive function due to their insulinotropic nature, but they also directly affect reproduction. Mice deficient in either GLP-1R or GIPR exhibit disrupted estrous cycling, reduced fertility, and smaller litter sizes [311], and GLP-1R knockout additionally leads to delayed puberty in female mice [312]. GLP-1 may exert many of these reproductive effects through central actions. Both hypothalamic GLP-1r expression and plasma GLP-1 concentrations vary across estrous phases in rats, and either central or peripheral administration of GLP-1 increases the preovulatory LH surge [313,314]. Intracerebral GLP-1 also synchronizes the onset of puberty, and improves implantation rates, birthing rates, and mature follicle numbers [314]. Changes in gonadotropin secretion appear to be due in part to GLP-1 positively regulating GnRH release. Early evidence in a rat hypothalamic cell-line pointed to GLP-1 promoting GnRH release via intracellular cAMP signaling [315], and subsequent work implicated the involvement of Kiss1 neurons [314,316,317] and GABAergic signals [318] in bolstering the direct effects of GLP-1 on GnRH neurons. While there is less known about the role of GIP, GIPR is expressed in the murine hypothalamus [319] and pituitary [311], and intracerebroventricular GIP administration decreases plasma FSH levels in rats [320]. Receptors for both GLP-1 and GIP are also expressed in the rodent ovary [311,321], and both of these incretins suppress progesterone synthesis in the presence of FSH [321]. Incretins have also been detected in human follicular fluid, and tend to be higher in the follicular fluid of obese women (particularly GLP-1) [322].

There has been some investigation into the therapeutic effects of incretin receptor agonists for female reproductive disorders. For instance, GLP-1 receptor analogues can mitigate the ovarian inflammation, fibrosis, oxidative stress, and AMH reduction that is induced in a rat model of diabetes [323]. In animal models of PCOS, incretin receptor agonists improve ovarian morphology and gonadotropin levels [324,325]. Incretin analogues are also being applied in clinical practice with PCOS patients. They can effectively alter steroid hormone levels [326–329], decrease body weight and enhance metabolic health [330–333], regularize menstrual cycling [329,331,334], and improve pregnancy rates and outcomes [331,333]. However, in general there is a paucity of information on the details and mechanisms by which anti-obesity pharmaceuticals such as incretin receptor agonists affect the female reproductive system [309,335].

First isolated in the 1940s, growth hormone (GH) was defined by impacts on longitudinal growth largely driven by a promotion of bone growth in children and adolescents [336,337]. However, it is now known that GH also has a broader reach in regulating energy balance, including effects on puberty timing, reproductive function, insulin resistance, metabolic fuel selection, lipolysis, hepatic glucose production, protein synthesis, muscle building, and immune function [337–339]. In general, GH is anabolic in nature. It stimulates an increase in lean body mass under energy-replete conditions, and preserves lean body mass and carbohydrate stores during fasting by promoting lipid usage [337]. GH elicits its physiological outcomes through a combination of indirect, IGF-1-mediated effects and direct intracellular signaling via the widely expressed GH receptor, which activates Janus kinase 2 (JAK2)-signal transducers and activators of transcription (STAT) as well as other signaling cascades [339]. Since GH promotes a rise in circulating and locally produced levels of the insulin-like growth factor IGF-1, it can be difficult to mechanistically distinguish between direct GH effects and ancillary effects carried out through IGF-1 signaling [337].

GH is secreted in a pulsatile manner by somatotroph cells in the anterior pituitary gland, with levels and patterns that depend on age, sex, and energy balance [340–342]. Hypothalamic-produced GH-releasing hormone stimulates its secretion while somatostatin inhibits it [340,343]. Additionally, ghrelin potently stimulates GH secretion, and both estrogens and androgens promote GH release [340,343–348]. Outside of the brain, GH mRNA is also expressed in peripheral tissues, including in the uterus, mammary glands, and ovaries; locally produced GH likely has local autocrine and/or paracrine effects, rather than traveling through circulation [349]. In general, circulating GH is higher in females than males, and levels rise in response to puberty, sleep, exercise, and fasting, whereas GH is decreased in response to elevated blood glucose, glucocorticoids, and aging [340,348]. Circulating GH levels peak at puberty and decline steadily afterwards, with only residual levels detectable at age 50 [350–354].

Growth hormone and the female reproductive system

Having sufficient GH is important for multiple facets of female reproductive competency. Women with GH deficiency have delayed menarche, fewer children, reduced uterine volume, low prolactin levels, and higher FSH [355,356]. Similarly, GH-deficient rodents have a later onset of puberty, smaller litter sizes, delayed parturition, irregular estrous cycles, and fewer corpora lutea and follicles [357–360]. GH replacement therapy has therapeutic potential in GH-deficient infertile women [361], and also improves ovulation rates and embryo implantation rates in women undergoing IVF when combined with gonadotropin treatment [362,363]. Genetically engineered GH-overexpressing animals have increased ovarian weights as well as higher ovulation rates and implantation sites, but also exhibit lower mating rates and reduced offspring survival [364,365].

In addition to regulating pubertal growth, GH is implicated in controlling the timing of puberty. Puberty is delayed in mammals with GH deficiency, although the fact that they can reach sexual maturation indicates that GH is not a requirement [366,367]. GH transgene expression expedites puberty in mice [365], and GH treatment in GH-deficient children stimulates an earlier age of puberty [368]. GH affects GnRH release [369,370], and GH and/or IGF-1 signaling in GnRH neurons or Kiss1 neurons could play a role in the activation of pulsatile hypothalamic GnRH secretion linked to the onset of puberty (reviewed in [366]). However, the start of ovarian steroidogenesis and consequential rise in steroid hormones is instrumental in promoting the steep elevation in GH levels during puberty, making it difficult to tease apart these causal relationships [366,367]. Ultimately, it is most likely that interactions between GH and the HPG axis are bidirectional during the complex endocrine shifts of puberty, and GH may be one of the integrated endocrine signals that conveys whether nutrient levels are sufficient for puberty to proceed [366,367].

At the level of the anterior pituitary, it is noteworthy that there are interactions between GH-producing somatotroph cells and gonadotropin-producing gonadotroph cells (reviewed in [367]). Therefore, GH likely exerts some of its reproductive effects within the pituitary itself, through such means as influencing the secretion of LH and FSH [367]. However, GH plays a more apparent role in regulating reproductive function through its ovarian actions.

In the ovary, GH is involved in governing gametogenesis, gonadotropin sensitivity, follicle survival, and the preservation of tissue health [371]. GH receptors are present in the oocytes and granulosa cells of antral follicles [372], and levels are significantly decreased in lower-quality oocytes of aging women [373]. In vitro studies of goat oocytes reveal that GH treatment stimulates early antral follicle development, promotes fertilization, development of healthy oocyte-cumulus complexes and growth of a healthy embryo [374]. Similarly, in canine oocytes GH acts alongside FSH to promote antrum formation, resulting in improved follicular viability [375]. Other studies have suggested that GH prevents follicular apoptosis via IGF-1 and the PI3K/AKT signaling pathway [376,377]. In vivo work has shown that GH may improve ovulation rates by increasing the number of superovulated oocytes reaching meiosis II [378]. In vitro studies point to a similar trend of GH supplementation leading to increased meiotic progression rates [374], and improved nuclear maturation in rodent [379], dog [380], sheep [381], bovine [382], equine [383], and human [384] oocytes. These effects may be partially mediated by cumulus cells. GH stimulates proliferation and inhibits apoptosis of cumulus cells [385,386], and regulates the expression of the gap junction proteins that allow oocytes to exchange nutrients with surrounding cumulus cells [385,387]. Murine oocytes cultured with GH form thecal layers that are rich in mitochondria and rough ER, implicating an additional role in theca cell proliferation [388].

The clinical potential for GH also stems from its role in improving uterine receptivity to incoming embryos. GH-stimulated upregulation of IGF-1 mediates estrogen-related improvements in endometrial receptivity and increase uterine thickness across several species [389–393]. Although more contentious, human studies also suggest benefits of GH therapy among female IVF and embryo transfer patients, especially if they have endocrine disorders or are overweight/obese [394,395]. GH concentrations are higher in the follicular fluid of oocytes that result in successful pregnancy [396,397], and GH supplementation increases oocyte yield as well as rates of pregnancies and live births with IVF [398,399]. Thus, GH is becoming an increasingly important compound-of-interest in assisted reproductive technologies [363,400–405].

Identified in 1999 as the endogenous ligand of the growth hormone secretagogue receptor (GHSR) [406], acetylated ghrelin is a gastric hormone involved in sensing nutrient availability and coordinating meal anticipation, which complements its stimulation of growth hormone secretion and other metabolic effects [407]. Dubbed the ‘hunger hormone’ for its appetite-boosting effects [408], acetylated ghrelin is in fact a multi-faceted hormone that also stimulates gastric acid secretion and gut motility, promotes adiposity, decreases insulin sensitivity, and modulates glucose and lipid metabolism [407,409]. Ghrelin and its receptor are both widely expressed in human tissues, including in reproductive and endocrine organs [410], but most circulating ghrelin originates from enteroendocrine cells of the stomach [411]. Levels rise before meals and during fasting, largely due to neural regulation of gastric ghrelin secretion; conversely, there is a postprandial drop in ghrelin in response to nutrients and bitter compounds in the gastrointestinal system as well as input by hormones such as insulin and leptin [408,409,411,412]. Circulating ghrelin exists in two distinct forms due to its enzyme-catalyzed acetylation. Less than 10% is acetylated and capable of binding to the GHSR, while des-acylated ghrelin functionally antagonizes acetylated ghrelin and may also have independent effects [407,409].

Ghrelin and the female reproductive system

As an orexigenic hormone that signals nutrient insufficiency, ghrelin is generally a negative modifier of female reproduction. Women with amenorrhea associated with intense exercise or anorexia have higher levels of ghrelin [413–415]. Ghrelin levels decline during childhood and into puberty [416], and pubertal onset in female rats is delayed by high doses of ghrelin [417–419]. High ghrelin or ghrelin analog treatment reduces rates of ovulation, pregnancy, fertilization, and embryo implantation in mice, and suppresses ovine embryo development [420–423]. Interestingly, ghrelin levels increase with age and over the menopausal transition [412,424,425], which may contribute to postmenopausal shift in metabolic health [426].

Central in vivo effects of ghrelin include decreasing GnRH secretion and pulsatility, as well as lowering LH and/or FSH [415,418,427–431]. The GHSR is expressed in regions of the hypothalamus [432,433], Kiss1 neurons [434], and pituitary gonadotrophs [435]. Although GnRH neurons themselves do not express this receptor, ghrelin might act via upstream neuronal regulators to suppress GnRH release [221]. In contrast, ghrelin can stimulate LH secretion by pituitary tissue in vitro, pointing to an opposing, tissue-specific mode of action that might depend on such factors as age, sex, and interacting gonadal inputs [417,418,436].

Ghrelin also exerts direct ovarian effects. Ghrelin expression has been documented in the ovaries of species ranging from chicken to human [437–443], including in oocytes, corpus lutea, and stromal cells [437,439,440]. Ghrelin injections lower estrogen and progesterone levels in female rats [444], and it acts directly through GHSR of corpus luteal cells to reduce progesterone secretion [445,446], pointing to a role in regulating steroidogenesis. Ghrelin may also contribute toward repressing follicle maturation: ghrelin administration leads to greater numbers of small follicles coupled with fewer corpus lutea in rat ovaries [447], whereas mice lacking endogenous acetylated ghrelin have a decrease in small follicles [448]. Generally, elevated ghrelin suppresses female reproductive functions both centrally and peripherally, which is consistent with a message of energy depletion.

Leptin, an indicator of stored fuel levels in adipose tissue, is involved in regulating long-term energy balance by influencing parameters such as energy expenditure, appetite, and reproductive function. Leptin is a peptide hormone principally secreted by adipocytes in white adipose tissue, though it can also be produced by other tissues such as the placenta, stomach, and skeletal muscle [449–453]. Serum leptin and adipocyte expression of the leptin gene (LEP or OB) are proportional to adipose tissue mass, with levels that generally rise with obesity and fall with weight loss [454]. LEP expression and circulating leptin are also affected by short-term energy imbalances, cytokines, the sympathetic nervous system, and other hormones such as insulin, glucocorticoids, and gonadal steroids [455]. In both humans and rodents, leptin levels are higher in females than in adiposity-matched males (particularly for premenopausal women); this is likely due to the regulation of leptin production by estrogens and testosterone, as well as sexual dimorphism in adipose tissue distribution [456–460]. Although leptin is not alone in controlling energy balance, its crucial role is evidenced by the excessive obesity, hyperphagia, and infertility of the leptin-deficient ob/ob mouse [461–463]. Similarly, rare mutations causing congenital leptin deficiency or leptin resistance in humans are associated with rapid weight gain, severe obesity, low gonadotropin levels, and delayed or absent puberty [464–467].

In response to elevated leptin—which indicates that energy balance has tipped towards abundant metabolic fuel stores—the hypothalamus induces a series of physiological processes that boost satiety and energy expenditure [467,468]. However, obesity is often coupled with both increased leptin levels and leptin resistance, which diminishes its effectiveness in promoting weight loss [467]. Low leptin levels correlate with reduced adiposity, which is interpreted by the hypothalamus as an energy deficit that requires neurological and physiological changes to promote food intake while reducing energy expenditure to restore energy balance [467].

The canonical leptin signaling pathway involves activation of JAK2 and phosphorylation of the transcription factor STAT3. However, due to pathway cross-talk leptin also activates other signal transduction cascades, such as the PI3K and MAPK pathways [468]. Only the full-length, long-form isoform of the leptin receptor has the intracellular domains required for signal transduction [469,470]. Although particularly abundant in the hypothalamus, there is nearly universal tissue distribution of leptin receptors, including expression of the long-form receptor in many brain regions and in the uterus and ovaries [469–472]. This highlights the fact that leptin signaling has a wide breadth of effects. In addition to its trademark impacts on appetite and energy expenditure, leptin is also involved in controlling lipolysis, immune function, angiogenesis, bone formation, and reproduction [468].

Leptin and the female reproductive system

Leptin is a fundamental regulator of female reproductive function that affects processes ranging from steroidogenesis and ovulation to puberty and pregnancy. Negative energy balance leads to decreased leptin, amenorrhea, and subfertility [473,474], and leptin administration in women with hypothalamic amenorrhea is sufficient to restore their menses and fertility, raise serum estradiol, and increase the number of dominant follicles [475–477]. Exogenous leptin also restores the fertility of ob/ob mice independent of body weight effects, by restoring HPG axis functioning [478,479]. Similarly, daily leptin injections in leptin-deficient children correct pubertal timing and gonadotropin pulsatility [480]. In rodents, leptin aids in pubertal activation of the HPG axis [481,482], although it alone cannot trigger puberty alone [478,483–486]. Low doses of leptin increase LH and FSH levels in mice [487], induce ovulation in an LH-dependent manner [488], and stimulate meiotic progression of bovine oocytes [489].

Leptin exerts some of these effects through indirect modulation of GnRH neurons and the pituitary. Leptin receptors are undetectable in murine GnRH neurons, and GnRH neuron-specific leptin receptor deletion does not affect fertility or puberty onset. However, mice lacking leptin receptors in all forebrain neurons have delayed puberty, severe infertility, and a suppressed estradiol-stimulated LH surge [490]. Leptin likely impacts GnRH release via upstream neuronal inputs [221], such as Kiss1 neurons [490–493]. It may also elicit direct effects on the pituitary [494], since cultured pituitary tissue dose-dependently releases LH, FSH and prolactin in response to leptin exposure [495].

There is also a relationship between leptin and the ovarian steroid hormones. LEP is expressed by granulosa, cumulus, and oocyte cells, with leptin protein detectable in mature follicles and follicular fluid [496,497]. Human and rat ovaries express leptin receptors on their theca, granulosa and interstitial cells [471,496–499], thus acting as target sites for leptin to regulate steroidogenesis. In vitro studies of human [499,500], bovine [501], and rat [502–504] cells or tissues have demonstrated that leptin attenuates steroid hormone production. Interestingly, there are reports of circulating leptin changing across the menstrual cycle, with a rise from menses into the luteal phase and a mid-cycle peak corresponding with the LH surge; leptin therefore shows some synchronicity with estradiol, progesterone, testosterone, and LH [475,505–507]. Some of these rhythmic changes may be due to leptin production by ovarian structures such as the corpus luteum [508,509]. However, leptin cyclicity during the menstrual cycle is controversial, with other studies reporting no differences [510–512].

During pregnancy, there is a two-fold increase in circulating leptin levels [513,514], due to both increased maternal adiposity and leptin secretion by the placenta [452]. As pregnancy progresses, the rise in leptin induces central resistance to its appetite-suppressing effects, and leptin takes on modified roles that include support of blastocyst formation, implantation, placentation, and human chorionic gonadotropin production [515–518]. Supraphysiological levels of leptin are associated with pregnancy disorders such as preeclampsia [519–524] and gestational diabetes [525]. Thus, leptin is involved in optimising and maintaining many aspects of female reproductive health and function.

In addition to leptin, adipocytes also secrete another signaling molecule in large quantities: adiponectin. First discovered and characterized in 1995–1996, adiponectin is a 244-amino acid protein [526–529] with insulin-sensitizing [530,531], anti-inflammatory [532], anti-atherogenic [532–535], and cardioprotective [536,537] properties. Adiponectin is primarily secreted by adipocytes, but has been detected in other tissues, including the brain [538,539], gonads [540,541], and placenta [542]. In contrast with leptin, adiponectin levels are inverse to adiposity; adiponectin is lower among obese individuals [543–545], and restricting caloric intake can increase circulating adiponectin [546]. Testosterone also reduces adiponectin secretion [547], which may contribute toward the lower levels in men compared with women [543,544]. There are no apparent repercussions of menopause, estrogen therapy or ovary removal for adiponectin levels [548–550].

Adiponectin signals through binding to adiponectin receptors 1 and 2 (AdipoR1 and AdipoR2), which are found abundantly among several tissues, but especially in the skeletal muscle and liver [551,552]. Ligand binding leads to a number of downstream signaling responses, including AMPK activation, mTOR inhibition, stimulation and cross-talk with the insulin/IGF-1 signaling pathways, and interactions with other signal transduction adaptor proteins [196]. These adiponectin-induced signaling cascades in central and peripheral tissues induce metabolically important responses. Exogenous adiponectin administration increases blood insulin levels in vivo [553], and promotes insulin gene expression and secretion in vitro [554]. Adiponectin-deficient mice develop hepatic insulin resistance and hyperglycemia, and are more sensitive to diet-induced metabolic dysfunction [530]. In addition, adiponectin-deficient female mice are subfertile, with altered menstrual cycles, altered gonadotropin profiles, reduced ovulation and a greater number of atretic follicles [555]. This points to a role in reproductive regulation.

Adiponectin and the female reproductive system

Adiponectin elicits both central and peripheral reproductive effects. Adiponectin receptors are found throughout the hypothalamus in a variety of species [556–558], and adiponectin is present in cerebrospinal fluid [557,559–562], which suggests a potential route of entry into the brain. Consistent with a function in promoting energy preservation, adiponectin suppresses GnRH secretion and inhibits Kiss1 gene expression by activating AMPK in a hypothalamic cell line [563,564], and it attenuates activity of a subpopulation of mouse GnRH neurons via AMPK activation [565]. Humans also express adiponectin and its receptors on pituitary cells, including gonadotrophs [566]. Adiponectin can reduce basal and GnRH-stimulated LH levels and GnRH receptor expression in cultured rodent pituitary cells [538,567], but reported effects are not consistent for pigs [568] or non-human primates [569].

In the ovary, adiponectin signaling influences oocyte maturation as well as the production and release of steroid hormones. Adiponectin and adiponectin receptors are expressed in ovarian theca cells, granulosa cells, oocytes, and corpus lutea [541,570–572], and levels appear somewhat responsive to gonadotropins [573–575]. Adiponectin regulates the expression of genes encoding steroidogenic enzymes and gonadotropin receptors, augments the IGF-1-stimulated release of progesterone and estradiol, and decreases androgen levels [541,570,576–579]. Adiponectin is also implicated in promoting oocyte meiotic maturation and early embryo development [572,580–583]. The mechanisms by which adiponectin exerts these ovarian effects have not been fully defined, but may involve interactions with the insulin/IGF-1 MAPK/ERK signaling pathway [541,570,576,579,581,582].

Low adiponectin (which can signify overabundant energy stores) is linked to reduced female reproductive health. Adiponectin levels are positively correlated with levels of the ovarian reserve biomarker AMH [215,584], and obesity corresponds with both low adiponectin and low AMH, among other endocrine changes [585]. Women with PCOS also have significantly lower adiponectin levels that correlate with lower metabolic health, compared with individuals matched for body mass index [586,587]. In addition, a decreased proportion of theca cells express adiponectin receptors in polycystic ovaries [588]. Low serum adiponectin or a low ratio of follicular fluid:serum adiponectin has been associated with unsuccessful IVF outcomes [589], higher rates of implantation failures [590], and low oocyte retrieval [591]. Therefore, adiponectin is yet another metabolic hormone at the nexus of metabolic health and reproductive function.

Research related to female reproductive health is disproportionately underfunded [592–595], with consequential impacts on the well-being of half the global population. Moreover, despite the existence of sex differences in the prevalence, pathophysiology, and responses to treatment of metabolic disorders such as Type 2 diabetes [9,10,596–598], a significant underrepresentation of female participants and female animals in metabolic health studies has persisted in recent decades [599–604]. As a result, each of these fields alone holds substantial knowledge gaps—to say nothing of the gaps in knowledge that exist at the interface of metabolic health and female reproductive health.

We believe that there are many critical questions at the junction of metabolism and reproduction. For instance:

  • While this review highlights effects of metabolic hormones on reproductive function, lines of communication between metabolic tissues and the reproductive system are bidirectional, and merit further study. For example, FSH was recently shown to regulate insulin secretion via FSH receptors expressed in pancreatic islets [605], and gonadal steroid hormones contribute towards sexual dimorphism in energy partitioning and metabolic homeostasis [8–10,606].

  • Exogenous hormonal contraceptives cause metabolic changes [607–609], and conversely, the presence of diabetes, obesity, and/or other metabolic disorders has implications for the systemic impacts of hormonal contraceptives [610,611]. Research into these intertwining effects is complicated by the heterogeneous nature of disorders such as Type 2 diabetes or polycystic ovary syndrome, in addition to wide variety in hormonal contraceptive formulations, and interplay of factors such as age, ethnicity, genetics, environment, and duration of contraceptive use [608,612].

  • Similar complications affect investigations of interactions between metabolic health and hormone replacement therapy, or between metabolic health and menstrual cycle characteristics, but these challenges should not preclude exploring such fundamental biomedical and biological topics.

  • Puberty, pregnancy, and perimenopause are defined by changes to the female reproductive system, and all three life stages also feature marked metabolic changes. For instance, insulin resistance and β-cell mass are transiently elevated during puberty [613–616] and during pregnancy [617–620], and the incidence or severity of metabolic syndrome increases significantly during perimenopause [621,622]. Therefore, it seems especially pertinent to understand the relationships between nutritional status, metabolic health, and female reproductive function during these transitional periods.

The high energetic requirements of supporting reproduction mean that the signaling systems communicating food intake, metabolic fuel stores, and energy levels play an integral role in regulating reproductive function. Consequently, impaired metabolic health has repercussions for female reproductive health that extend beyond fertility or fetal effects. Changes to nutritional status induce a suite of responses, and it is necessary to consider the context of a broad landscape of nutrient- and energy-responsive signaling systems instead of focusing on isolated hormones under specific conditions. For instance, food ingestion or a surplus of energy stores generally leads to increased levels of insulin, GIP, GLP-1, and leptin, together with suppression of growth hormone, ghrelin, and adiponectin; energy deficits tend to cause the opposite endocrine shifts (Figure 1). Each of these hormones can cause their own effects within the reproductive axis, in addition to generating signaling pathway cross-talk and interplay with other hormones. Moreover, the precise effects of each hormone might vary depending on nutritional conditions and interacting signaling factors. Delineating the complexities of these mechanistic relationships is essential for understanding how metabolic disorders or energy imbalance deregulates female reproductive health.

The authors declare that there are no competing interests associated with the manuscript.

The Templeman laboratory is supported by funding from the Canadian Institutes of Health Research [grant number PJT-183618] and the Natural Sciences Engineering Research Council of Canada [grant number RGPIN-2022-05149]. N.M.T. is a Tier 2 Canada Research Chair in Cell Biology and a Michael Smith Health Research BC Scholar, and this work was undertaken in part thanks to funding from the Canada Research Chairs Program and Michael Smith Health Research BC.

Faria Athar: Writing—original draft. Muskan Karmani: Visualization, Writing—original draft. Nicole M. Templeman: Writing—original draft, Writing—review & editing.

AdipoR

adiponectin receptor

AdipoR1 and AdipoR2

adiponectin receptors 1 and 2

AMH

anti-müllerian hormone

AMPK

AMP- activated protein kinase

FSH

follicle-stimulating hormone

GH

growth hormone

GHSR

growth hormone secretagogue receptor

GIP

glucose-dependent insulinotropic polypeptide

GLP-1

glucagon-like peptide 1

GnRH

Gonadotropin-releasing hormone

HPG

hypothalamic-pituitary-gonadal

IGF-1

insulin-like growth factor 1

InsR

insulin receptor

JAK2

janus kinase 2

Kiss1

kisspeptin

LH

luteinizing hormone

MAPK

mitogen-activated protein kinase

mTOR

mechanistic target of rapamycin

PCOS

polycystic ovary syndrome

PI3K

phosphatidylinositol 3-kinase

STAT

signal transducers and activators of transcription

1.
Schneider
J.
,
Klingerman
C.
and
Abdulhay
A.
(
2012
)
Sense and nonsense in metabolic control of reproduction
.
Front Endocrinol.
3
,
26
2.
Ball
G.F.
and
Ketterson
E.D.
(
2007
)
Sex differences in the response to environmental cues regulating seasonal reproduction in birds
.
Philos. Trans. R. Soc. B Biol. Sci.
363
,
231
246
3.
Thomas
D.W.
,
Blondel
J.
,
Perret
P.
,
Lambrechts
M.M.
and
Speakman
J.R.
(
2001
)
Energetic and Fitness costs of mismatching resource supply and demand in seasonally breeding birds
.
Science
291
,
2598
2600
[PubMed]
4.
Luquet
P.
and
Watanabe
T.
(
1986
)
Interaction “nutrition-reproduction” in fish
.
Fish Physiol. Biochem.
2
,
121
129
[PubMed]
5.
Rideout
R.M.
,
Rose
G.A.
and
Burton
M.P.M.
(
2005
)
Skipped spawning in female iteroparous fishes
.
Fish Fish
6
,
50
72
6.
Karp
X.
(
2021
)
Hormonal regulation of diapause and development in nematodes, insects, and fishes
.
Front Ecol. Evol.
9
,
735924
7.
Short
C.A.
and
Hahn
D.A.
(
2023
)
Fat enough for the winter? Does nutritional status affect diapause?
J. Insect Physiol.
145
,
104488
[PubMed]
8.
Bond
S.T.
,
Calkin
A.C.
and
Drew
B.G.
(
2021
)
Sex differences in white adipose tissue expansion: emerging molecular mechanisms
.
Clin. Sci.
135
,
2691
2708
9.
Mauvais-Jarvis
F.
(
2015
)
Sex differences in metabolic homeostasis, diabetes, and obesity
.
Biol. Sex Differ.
6
,
14
[PubMed]
10.
Tramunt
B.
,
Smati
S.
,
Grandgeorge
N.
,
Lenfant
F.
,
Arnal
J.-F.
,
Montagner
A.
et al.
(
2020
)
Sex differences in metabolic regulation and diabetes susceptibility
.
Diabetologia
63
,
453
461
[PubMed]
11.
Meczekalski
B.
,
Tonetti
A.
,
Monteleone
P.
,
Bernardi
F.
,
Luisi
S.
,
Stomati
M.
et al.
(
2000
)
Hypothalamic amenorrhea with normal body weight: ACTH, allopregnanolone and cortisol responses to corticotropin-releasing hormone test
.
Eur. J. Endocrinol.
142
,
280
285
[PubMed]
12.
Bomba
M.
,
Gambera
A.
,
Bonini
L.
,
Peroni
M.
,
Neri
F.
,
Scagliola
P.
et al.
(
2007
)
Endocrine profiles and neuropsychologic correlates of functional hypothalamic amenorrhea in adolescents
.
Fertil. Steril.
87
,
876
885
[PubMed]
13.
Perkins
R.B.
,
Hall
J.E.
and
Martin
K.A.
(
2001
)
Aetiology, previous menstrual function and patterns of neuro-endocrine disturbance as prognostic indicators in hypothalamic amenorrhoea
.
Hum. Reprod.
16
,
2198
2205
[PubMed]
14.
Golden
N.H.
and
Carlson
J.L.
(
2008
)
The pathophysiology of amenorrhea in the adolescent
.
Ann. N. Y. Acad. Sci.
1135
,
163
178
[PubMed]
15.
Frisch
R.E.
,
Wyshak
G.
and
Vincent
L.
(
1980
)
Delayed menarche and amenorrhea in ballet dancers
.
N. Engl. J. Med.
303
,
17
19
[PubMed]
16.
Warren
M.P.
(
1980
)
The effects of exercise on pubertal progression and reproductive function in girls
.
J. Clin. Endocrinol. Metab.
51
,
1150
1157
[PubMed]
17.
Frisch
R.E.
,
Gotz-Welbergen
A.V.
,
McArthur
J.W.
,
Albright
T.
,
Witschi
J.
,
Bullen
B.
et al.
(
1981
)
Delayed menarche and amenorrhea of college athletes in relation to age of onset of training
.
JAMA
246
,
1559
1563
[PubMed]
18.
Ravi
S.
,
Valtonen
M.
,
Ihalainen
J.K.
,
Holopainen
E.
,
Kosola
S.
,
Heinonen
S.
et al.
(
2023
)
Eating behaviours, menstrual history and the athletic career: a retrospective survey from adolescence to adulthood in female endurance athletes
.
BMJ Open Sport Exerc. Med.
9
,
e001489
[PubMed]
19.
Golden
N.H.
and
Shenker
I.R.
(
1994
)
Amenorrhea in anorexia nervosa. Neuroendocrine control of hypothalamic dysfunction
.
Int. J. Eat. Disord.
16
,
53
60
[PubMed]
20.
Warren
M.P.
(
2011
)
Endocrine manifestations of eating disorders
.
J. Clin. Endocrinol. Metab.
96
,
333
343
[PubMed]
21.
Hetland
M.L.
,
Haarbo
J.
,
Christiansen
C.
and
Larsen
T.
(
1993
)
Running induces menstrual disturbances but bone mass is unaffected, except in amenorrheic women
.
Am. J. Med.
95
,
53
60
[PubMed]
22.
Morrison
A.E.
,
Fleming
S.
and
Levy
M.J.
(
2021
)
A review of the pathophysiology of functional hypothalamic amenorrhoea in women subject to psychological stress, disordered eating, excessive exercise or a combination of these factors
.
Clin. Endocrinol. (Oxf)
95
,
229
238
[PubMed]
23.
Højlund
K.
,
Wildner-Christensen
M.
,
Eshøj
O.
,
Skjærbæk
C.
,
Holst
J.J.
,
Koldkjær
O.
et al.
(
2001
)
Reference intervals for glucose, β-cell polypeptides, and counterregulatory factors during prolonged fasting
.
Am. J. Physiol.-Endocrinol. Metab.
280
,
E50
E58
[PubMed]
24.
Fahrenholtz
I.L.
,
Sjödin
A.
,
Benardot
D.
,
Tornberg
Å.B.
,
Skouby
S.
,
Faber
J.
et al.
(
2018
)
Within-day energy deficiency and reproductive function in female endurance athletes
.
Scand. J. Med. Sci. Sports
28
,
1139
1146
[PubMed]
25.
Kumar
S.
and
Kaur
G.
(
2013
)
Intermittent fasting dietary restriction regimen negatively influences reproduction in young rats: a study of hypothalamo-hypophysial-gonadal axis
.
PLoS ONE
8
,
e52416
[PubMed]
26.
Khoshdel
A.
,
Kheiri
S.
,
Hashemi-Dehkordi
E.
,
Nasiri
J.
,
Shabanian-Borujeni
S.
and
Saedi
E.
(
2014
)
The effect of Ramadan fasting on LH, FSH, oestrogen, progesterone and leptin in pregnant women
.
J. Obstet. Gynaecol. J. Inst. Obstet. Gynaecol.
34
,
634
638
27.
Cameron
J.L.
and
Nosbisch
C.
(
1991
)
Suppression of pulsatile luteinizing hormone and testosterone secretion during short term food restriction in the adult male rhesus monkey. (Macaca mulatta)
.
Endocrinology
128
,
1532
1540
[PubMed]
28.
Gopalan
C.
and
Nadamuni Naidu
A.
(
1972
)
Nutrition and fertility
.
Lancet North Am. Ed.
300
,
1077
1079
29.
Amegah
A.K.
,
Damptey
O.K.
,
Sarpong
G.A.
,
Duah
E.
,
Vervoorn
D.J.
and
Jaakkola
J.J.K.
(
2013
)
Malaria infection, poor nutrition and indoor air pollution mediate socioeconomic differences in adverse pregnancy outcomes in Cape Coast, Ghana
.
PLoS One
8
,
e69181
[PubMed]
30.
Jamshed
S.
,
Khan
F.-
,
Begum
A.
,
Barkat Ali
B.
,
Akram
Z.
and
Ariff
M.
(
2020
)
Frequency of low birth weight and its relationship with maternal nutritional and dietary factors: a cross-sectional study
.
Cureus
12
,
e8731
[PubMed]
31.
Girsen
A.I.
,
Mayo
J.A.
,
Carmichael
S.L.
,
Phibbs
C.S.
,
Shachar
B.Z.
,
Stevenson
D.K.
et al.
(
2016
)
Women's prepregnancy underweight as a risk factor for preterm birth: a retrospective study
.
BJOG Int. J. Obstet. Gynaecol.
123
,
2001
2007
32.
Cates
J.E.
,
Unger
H.W.
,
Briand
V.
,
Fievet
N.
,
Valea
I.
,
Tinto
H.
et al.
(
2017
)
Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data
.
PLoS Med.
14
,
e1002373
[PubMed]
33.
Williams
N.I.
,
Helmreich
D.L.
,
Parfitt
D.B.
,
Caston-Balderrama
A.
and
Cameron
J.L.
(
2001
)
Evidence for a causal role of low energy availability in the induction of menstrual cycle disturbances during strenuous exercise training
.
J. Clin. Endocrinol. Metab.
86
,
5184
5193
[PubMed]
34.
Szymanski
L.A.
,
Schneider
J.E.
,
Friedman
M.I.
,
Ji
H.
,
Kurose
Y.
,
Blache
D.
et al.
(
2007
)
Changes in insulin, glucose and ketone bodies, but not leptin or body fat content precede restoration of luteinising hormone secretion in ewes
.
J. Neuroendocrinol.
19
,
449
460
[PubMed]
35.
Jones
J.E.
and
Lubbers
L.S.
(
2001
)
Suppression and recovery of estrous behavior in Syrian hamsters after changes in metabolic fuel availability
.
Am. J. Physiol.-Regul. Integr. Comp. Physiol.
280
,
R1393
R1398
[PubMed]
36.
Schneider
J.E.
,
Blum
R.M.
and
Wade
G.N.
(
2000
)
Metabolic control of food intake and estrous cycles in Syrian hamsters. I. Plasma insulin and leptin
.
Am. J. Physiol. Regul. Integr. Comp. Physiol.
278
,
R476
R485
[PubMed]
37.
Schneider
J.E.
and
Wade
G.N.
(
1990
)
Decreased availability of metabolic fuels induces anestrus in golden hamsters
.
Am. J. Physiol.-Regul. Integr. Comp. Physiol.
258
,
R750
R755
38.
Schneider
J.E.
and
Wade
G.N.
(
1989
)
Availability of metabolic fuels controls estrous cyclicity of Syrian hamsters
.
Science
244
,
1326
1328
[PubMed]
39.
Lado-Abeal
J.
,
Clapper
J.A.
,
Chen Zhu
B.
,
Hough
C.M.
,
Syapin
P.J.
and
Norman
R.L.
(
2002
)
Hypoglycemia-induced suppression of luteinizing hormone. (LH) secretion in intact female rhesus macaques: role of vasopressin and endogenous opioids
.
Stress Amst. Neth.
5
,
113
119
40.
Mircea
C.N.
,
Lujan
M.E.
and
Pierson
R.A.
(
2007
)
Metabolic Fuel and Clinical Implications for Female Reproduction
.
J. Obstet. Gynaecol. Can.
29
,
887
902
[PubMed]
41.
Bucholtz
D.C.
,
Vidwans
N.M.
,
Herbosa
C.G.
,
Schillo
K.K.
and
Foster
D.L.
(
1996
)
Metabolic interfaces between growth and reproduction. V. Pulsatile luteinizing hormone secretion is dependent on glucose availability
.
Endocrinology
137
,
601
607
[PubMed]
42.
Roland
A.V.
and
Moenter
S.M.
(
2011
)
Regulation of gonadotropin-releasing hormone neurons by glucose
.
Trends Endocrinol. Metab. TEM
22
,
443
449
43.
Kinoshita
M.
,
Moriyama
R.
,
Tsukamura
H.
and
Maeda
K.-I.
(
2003
)
A rat model for the energetic regulation of gonadotropin secretion: role of the glucose-sensing mechanism in the brain
.
Domest. Anim. Endocrinol.
25
,
109
120
[PubMed]
44.
Nappi
R.E.
,
Chedraui
P.
,
Lambrinoudaki
I.
and
Simoncini
T.
(
2022
)
Menopause: a cardiometabolic transition
.
Lancet Diab. Endocrinol.
10
,
442
456
45.
Cheng
C.-H.
,
Chen
L.-R.
and
Chen
K.-H.
(
2022
)
Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover
.
Int. J. Mol. Sci.
23
,
1376
[PubMed]
46.
Hogervorst
E.
,
Craig
J.
and
O'Donnell
E.
(
2022
)
Cognition and mental health in menopause: a review
.
Best Pract. Res. Clin. Obstet. Gynaecol.
81
,
69
84
[PubMed]
47.
Baker
L.
,
Meldrum
K.K.
,
Wang
M.
,
Sankula
R.
,
Vanam
R.
,
Raiesdana
A.
et al.
(
2003
)
The role of estrogen in cardiovascular disease
.
J. Surg. Res.
115
,
325
344
[PubMed]
48.
Lanyon
L.E.
(
1996
)
Using functional loading to influence bone mass and architecture: objectives, mechanisms, and relationship with estrogen of the mechanically adaptive process in bone
.
Bone
18
,
S37
S43
49.
Kalervo Väänänen
H.
and
Härkönen
P.L.
(
1996
)
Estrogen and bone metabolism
.
Maturitas
23
,
S65
S69
[PubMed]
50.
Schiessl
H.
,
Frost
H.M.
and
Jee
W.S.S.
(
1998
)
Estrogen and bone-muscle strength and mass relationships
.
Bone
22
,
1
6
[PubMed]
51.
Shufelt
C.L.
,
Torbati
T.
and
Dutra
E.
(
2017
)
Hypothalamic amenorrhea and the long-term health consequences
.
Semin. Reprod. Med.
35
,
256
262
[PubMed]
52.
Kearney
J.
(
2010
)
Food consumption trends and drivers
.
Philos. Trans. R. Soc. B. Biol. Sci.
365
,
2793
2807
53.
Nardocci
M.
,
Leclerc
B.-S.
,
Louzada
M.-L.
,
Monteiro
C.A.
,
Batal
M.
and
Moubarac
J.-C.
(
2018
)
Consumption of ultra-processed foods and obesity in Canada
.
Can J. Public Health Rev. Can Santé Publique
110
,
4
14
54.
Abarca-Gómez
L.
,
Abdeen
Z.A.
,
Hamid
Z.A.
,
Abu-Rmeileh
N.M.
,
Acosta-Cazares
B.
,
Acuin
C.
et al.
(
2017
)
Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults
.
Lancet North Am. Ed.
390
,
2627
2642
55.
Speakman
J.R.
,
de Jong
J.M.A.
,
Sinha
S.
,
Westerterp
K.R.
,
Yamada
Y.
,
Sagayama
H.
et al.
(
2023
)
Total daily energy expenditure has declined over the past three decades due to declining basal expenditure, not reduced activity expenditure
.
Nat. Metab.
5
,
579
588
[PubMed]
56.
Swinburn
B.A.
,
Sacks
G.
,
Hall
K.D.
,
McPherson
K.
,
Finegood
D.T.
,
Moodie
M.L.
et al.
(
2011
)
The global obesity pandemic: shaped by global drivers and local environments
.
Lancet North Am. Ed.
378
,
804
814
57.
Hohos
N.M.
and
Skaznik-Wikiel
M.E.
(
2017
)
High-fat diet and female fertility
.
Endocrinology
158
,
2407
2419
[PubMed]
58.
Skaznik-Wikiel
M.E.
,
Swindle
D.C.
,
Allshouse
A.A.
,
Polotsky
A.J.
and
McManaman
J.L.
(
2016
)
High-fat diet causes subfertility and compromised ovarian function independent of obesity in mice
.
Biol. Reprod.
94
,
108
[PubMed]
59.
Hohos
N.M.
,
Cho
K.J.
,
Swindle
D.C.
and
Skaznik-Wikiel
M.E.
(
2018
)
High-fat diet exposure, regardless of induction of obesity, is associated with altered expression of genes critical to normal ovulatory function
.
Mol. Cell. Endocrinol.
470
,
199
207
[PubMed]
60.
Gonnella
F.
,
Konstantinidou
F.
,
Di Berardino
C.
,
Capacchietti
G.
,
Peserico
A.
,
Russo
V.
et al.
(
2022
)
A systematic review of the effects of high-fat diet exposure on oocyte and follicular quality: a molecular point of view
.
Int. J. Mol. Sci.
23
,
8890
[PubMed]
61.
Lee
J.M.
,
Appugliese
D.
,
Kaciroti
N.
,
Corwyn
R.F.
,
Bradley
R.H.
and
Lumeng
J.C.
(
2007
)
Weight status in young girls and the onset of puberty
.
Pediatrics
119
,
e624
e630
[PubMed]
62.
Davison
K.K.
,
Susman
E.J.
and
Birch
L.L.
(
2003
)
Percent body fat at age 5 predicts earlier pubertal development among girls at age 9
.
Pediatrics
111
,
815
821
[PubMed]
63.
Biro
F.M.
,
Pajak
A.
,
Wolff
M.S.
,
Pinney
S.M.
,
Windham
G.C.
,
Galvez
M.P.
et al.
(
2018
)
Age of menarche in a longitudinal US cohort
.
J. Pediatr. Adolesc. Gynecol.
31
,
339
345
[PubMed]
64.
Bralić
I.
,
Tahirović
H.
,
Matanić
D.
,
Vrdoljak
O.
,
Stojanović-Spehar
S.
,
Kovacić
V.
et al.
(
2012
)
Association of early menarche age and overweight/obesity
.
J. Pediatr. Endocrinol. Metab. JPEM
25
,
57
62
65.
Barros B de
S.
,
Kuschnir
M.C.M.C.
,
Bloch
K.V.
and
da Silva
T.L.N.
(
2019
)
ERICA: age at menarche and its association with nutritional status
.
J. Pediatr. (Rio. J)
95
,
106
111
[PubMed]
66.
Hillman
J.B.
,
Miller
R.J.
and
Inge
T.H.
(
2011
)
Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients
.
J. Womens Health 2002
20
,
533
538
67.
Ko
K.M.
,
Han
K.
,
Chung
Y.J.
,
Yoon
K.H.
,
Park
Y.G.
and
Lee
S.H.
(
2017
)
Association between body weight changes and menstrual irregularity: the Korea National Health and Nutrition Examination Survey 2010 to 2012
.
Endocrinol. Metab. Seoul Korea
32
,
248
256
68.
Wei
S.
,
Schmidt
M.D.
,
Dwyer
T.
,
Norman
R.J.
and
Venn
A.J.
(
2009
)
Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin
.
Obes. Silver Spring Md.
17
,
1070
1076
69.
He
Y.
,
Tian
J.
,
Blizzard
L.
,
Oddy
W.H.
,
Dwyer
T.
,
Bazzano
L.A.
et al.
(
2020
)
Associations of childhood adiposity with menstrual irregularity and polycystic ovary syndrome in adulthood: the Childhood Determinants of Adult Health Study and the Bogalusa Heart Study
.
Hum Reprod. Oxf. Engl.
35
,
1185
1198
70.
Silvestris
E.
,
de Pergola
G.
,
Rosania
R.
and
Loverro
G.
(
2018
)
Obesity as disruptor of the female fertility
.
Reprod. Biol. Endocrinol. RBE
16
,
22
71.
Pasquali
R.
,
Patton
L.
and
Gambineri
A.
(
2007
)
Obesity and infertility
.
Curr. Opin. Endocrinol. Diab. Obes.
14
,
482
72.
Dağ
Z.Ö.
and
Dilbaz
B.
(
2015
)
Impact of obesity on infertility in women
.
J. Turk. Ger. Gynecol. Assoc.
16
,
111
117
[PubMed]
73.
Talmor
A.
and
Dunphy
B.
(
2015
)
Female Obesity and Infertility
.
Best Pract. Res. Clin. Obstet. Gynaecol.
29
,
498
506
[PubMed]
74.
Lashen
H.
,
Fear
K.
and
Sturdee
D.W.
(
2004
)
Obesity is associated with increased risk of first trimester and recurrent miscarriage: matched case-control study
.
Hum. Reprod. Oxf. Engl.
19
,
1644
1646
75.
Fedorcsák
P.
,
Dale
P.O.
,
Storeng
R.
,
Ertzeid
G.
,
Bjercke
S.
,
Oldereid
N.
et al.
(
2004
)
Impact of overweight and underweight on assisted reproduction treatment
.
Hum. Reprod. Oxf. Engl.
19
,
2523
2528
76.
Bellver
J.
,
Rossal
L.P.
,
Bosch
E.
,
Zúñiga
A.
,
Corona
J.T.
,
Meléndez
F.
et al.
(
2003
)
Obesity and the risk of spontaneous abortion after oocyte donation
.
Fertil. Steril.
79
,
1136
1140
[PubMed]
77.
Leddy
M.A.
,
Power
M.L.
and
Schulkin
J.
(
2008
)
The impact of maternal obesity on maternal and fetal health
.
Rev. Obstet. Gynecol.
1
,
170
178
[PubMed]
78.
Persson
M.
,
Cnattingius
S.
,
Villamor
E.
,
Söderling
J.
,
Pasternak
B.
,
Stephansson
O.
et al.
(
2017
)
Risk of major congenital malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons
.
BMJ
357
,
j2563
[PubMed]
79.
Castro
L.C.
and
Avina
R.L.
(
2002
)
Maternal obesity and pregnancy outcomes
.
Curr. Opin. Obstet. Gynecol.
14
,
601
[PubMed]
80.
Ray
J.G.
,
Wyatt
P.R.
,
Vermeulen
M.J.
,
Meier
C.
and
Cole
D.E.C.
(
2005
)
Greater maternal weight and the ongoing risk of neural tube defects after folic acid flour fortification
.
Obstet. Gynecol.
105
,
261
265
[PubMed]
81.
Watkins
M.L.
,
Rasmussen
S.A.
,
Honein
M.A.
,
Botto
L.D.
and
Moore
C.A.
(
2003
)
Maternal obesity and risk for birth defects
.
Pediatrics
111
,
1152
1158
[PubMed]
82.
Cedergren
M.I.
and
Källén
B.A.J.
(
2003
)
Maternal obesity and infant heart defects
.
Obes. Res.
11
,
1065
1071
[PubMed]
83.
Nagel
G.
,
Altenburg
H.P.
,
Nieters
A.
,
Boffetta
P.
and
Linseisen
J.
(
2005
)
Reproductive and dietary determinants of the age at menopause in EPIC-Heidelberg
.
Maturitas
52
,
337
347
[PubMed]
84.
Dunneram
Y.
,
Greenwood
D.C.
,
Burley
V.J.
and
Cade
J.E.
(
2018
)
Dietary intake and age at natural menopause: results from the UK Women's Cohort Study
.
J. Epidemiol. Community Health
72
,
733
740
[PubMed]
85.
Gambineri
A.
,
Pelusi
C.
,
Vicennati
V.
,
Pagotto
U.
and
Pasquali
R.
(
2002
)
Obesity and the polycystic ovary syndrome
.
Int. J. Obes. Relat. Metab. Disord. J. Int. Assoc. Study Obes.
26
,
883
896
86.
Rodriguez Paris
V.
,
Solon-Biet
S.M.
,
Senior
A.M.
,
Edwards
M.C.
,
Desai
R.
,
Tedla
N.
et al.
(
2020
)
Defining the impact of dietary macronutrient balance on PCOS traits
.
Nat. Commun.
11
,
5262
[PubMed]
87.
Witchel
S.F.
,
Oberfield
S.E.
and
Peña
A.S.
(
2019
)
Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls
.
J. Endocr. Soc.
3
,
1545
1573
[PubMed]
88.
Teede
H.
,
Deeks
A.
and
Moran
L.
(
2010
)
Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan
.
BMC Med.
8
,
41
[PubMed]
89.
Diamanti-Kandarakis
E.
and
Dunaif
A.
(
2012
)
Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications
.
Endocr. Rev.
33
,
981
1030
[PubMed]
90.
de Melo
A.S.
,
Dias
S.V.
,
de Carvalho Cavalli
R.
,
Cardoso
V.C.
,
Bettiol
H.
,
Barbieri
M.A.
et al.
(
2015
)
Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause
.
Reprod. Camb. Engl.
150
,
R11
R24
91.
Poretsky
L.
,
Cataldo
N.A.
,
Rosenwaks
Z.
and
Giudice
L.C.
(
1999
)
The insulin-related ovarian regulatory system in health and disease
.
Endocr. Rev.
20
,
535
582
[PubMed]
92.
Rosenfield
R.L.
and
Ehrmann
D.A.
(
2016
)
The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited
.
Endocr. Rev.
37
,
467
520
[PubMed]
93.
Villa
J.
and
Pratley
R.E.
(
2011
)
Adipose tissue dysfunction in polycystic ovary syndrome
.
Curr. Diab. Rep.
11
,
179
184
[PubMed]
94.
Delitala
A.P.
,
Capobianco
G.
,
Delitala
G.
,
Cherchi
P.L.
and
Dessole
S.
(
2017
)
Polycystic ovary syndrome, adipose tissue and metabolic syndrome
.
Arch. Gynecol. Obstet.
296
,
405
419
[PubMed]
95.
Kershaw
E.E.
and
Flier
J.S.
(
2004
)
Adipose tissue as an endocrine organ
.
J. Clin. Endocrinol. Metab.
89
,
2548
2556
[PubMed]
96.
Guo
W.
,
Wang
Y.
,
Ma
Y.
,
Cui
Z.
,
Zhang
L.
,
Nie
L.
et al.
(
2021
)
Contribution of high-fat diet-induced PCSK9 upregulation to a mouse model of PCOS is mediated partly by SREBP2
.
Reproduction
162
,
397
410
[PubMed]
97.
Zheng
Y.-H.
,
Xu
Y.
,
Ma
H.-X.
,
Liang
C.-J.
and
Yang
T.
(
2021
)
Effect of high-fat diet on the intestinal flora in letrozole-induced polycystic ovary syndrome rats
.
Evid. Based Complement Alternat. Med.
2021
,
e6674965
98.
Zhang
H.
,
Yi
M.
,
Zhang
Y.
,
Jin
H.
,
Zhang
W.
,
Yang
J.
et al.
(
2016
)
High-fat diets exaggerate endocrine and metabolic phenotypes in a rat model of DHEA-induced PCOS
.
Reprod. Camb. Engl.
151
,
431
441
99.
Boomsma
C.M.
,
Eijkemans
M.J.C.
,
Hughes
E.G.
,
Visser
G.H.A.
,
Fauser
B.C.J.M.
and
Macklon
N.S.
(
2006
)
A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome
.
Hum. Reprod. Update
12
,
673
683
[PubMed]
100.
Lo
J.C.
,
Feigenbaum
S.L.
,
Escobar
G.J.
,
Yang
J.
,
Crites
Y.M.
and
Ferrara
A.
(
2006
)
Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome: a population-based study
.
Diabetes Care
29
,
1915
1917
[PubMed]
101.
Legro
R.S.
(
2007
)
Pregnancy considerations in women with polycystic ovary syndrome
.
Clin. Obstet. Gynecol.
50
,
295
304
[PubMed]
102.
Sawada
M.
,
Masuyama
H.
,
Hayata
K.
,
Kamada
Y.
,
Nakamura
K.
and
Hiramatsu
Y.
(
2015
)
Pregnancy complications and glucose intolerance in women with polycystic ovary syndrome
.
Endocr. J.
62
,
1017
1023
[PubMed]
103.
Manoharan
V.
and
Wong
V.W.
(
2020
)
Impact of comorbid polycystic ovarian syndrome and gestational diabetes mellitus on pregnancy outcomes: a retrospective cohort study
.
BMC Pregnancy Childbirth
20
,
484
[PubMed]
104.
Roos
N.
,
Kieler
H.
,
Sahlin
L.
,
Ekman-Ordeberg
G.
,
Falconer
H.
and
Stephansson
O.
(
2011
)
Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study
.
BMJ
343
,
d6309
[PubMed]
105.
de Vries
M.J.
,
Dekker
G.A.
and
Schoemaker
J.
(
1998
)
Higher risk of preeclampsia in the polycystic ovary syndrome: A case control study
.
Eur. J. Obstet. Gynecol. Reprod. Biol.
76
,
91
95
[PubMed]
106.
Rees
D.A.
,
Jenkins-Jones
S.
and
Morgan
C.L.
(
2016
)
Contemporary reproductive outcomes for patients with polycystic ovary syndrome: a retrospective observational study
.
J. Clin. Endocrinol. Metab.
101
,
1664
1672
[PubMed]
107.
Ashrafi
M.
,
Sheikhan
F.
,
Arabipoor
A.
,
Hosseini
R.
,
Nourbakhsh
F.
and
Zolfaghari
Z.
(
2014
)
Gestational diabetes mellitus risk factors in women with polycystic ovary syndrome. (PCOS)
.
Eur. J. Obstet. Gynecol. Reprod. Biol.
181
,
195
199
[PubMed]
108.
Mills
G.
,
Badeghiesh
A.
,
Suarthana
E.
,
Baghlaf
H.
and
Dahan
M.H.
(
2020
)
Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies
.
Hum. Reprod. Oxf. Engl.
35
,
1666
1674
109.
Toulis
K.A.
,
Goulis
D.G.
,
Kolibianakis
E.M.
,
Venetis
C.A.
,
Tarlatzis
B.C.
and
Papadimas
I.
(
2009
)
Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis
.
Fertil. Steril.
92
,
667
677
[PubMed]
110.
Wild
S.
,
Pierpoint
T.
,
Jacobs
H.
and
McKeigue
P.
(
2000
)
Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study
.
Hum Fertil. Camb. Engl.
3
,
101
105
111.
Pierpoint
T.
,
McKeigue
P.M.
,
Isaacs
A.J.
,
Wild
S.H.
and
Jacobs
H.S.
(
1998
)
Mortality of women with polycystic ovary syndrome at long-term follow-up
.
J. Clin. Epidemiol.
51
,
581
586
[PubMed]
112.
Legro
R.S.
,
Kunselman
A.R.
,
Dodson
W.C.
and
Dunaif
A.
(
1999
)
Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women
.
J. Clin. Endocrinol. Metab.
84
,
165
169
[PubMed]
113.
Cheang
K.I.
,
Nestler
J.E.
and
Futterweit
W.
(
2008
)
Risk of cardiovascular events in mothers of women with polycystic ovary syndrome
.
Endocr. Pract. Off. J. Am. Coll Endocrinol. Am. Assoc. Clin. Endocrinol.
14
,
1084
1094
114.
Joham
A.E.
,
Boyle
J.A.
,
Zoungas
S.
and
Teede
H.J.
(
2015
)
Hypertension in reproductive-aged women with polycystic ovary syndrome and association with obesity
.
Am. J. Hypertens.
28
,
847
851
[PubMed]
115.
Ding
D.-C.
,
Tsai
I.-J.
,
Wang
J.-H.
,
Lin
S.-Z.
and
Sung
F.-C.
(
2018
)
Coronary artery disease risk in young women with polycystic ovary syndrome
.
Oncotarget
9
,
8756
8764
[PubMed]
116.
Glintborg
D.
,
Hass Rubin
K.
,
Nybo
M.
,
Abrahamsen
B.
and
Andersen
M.
(
2015
)
Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome
.
Eur. J. Endocrinol.
172
,
627
638
[PubMed]
117.
Sirmans
S.M.
,
Parish
R.C.
,
Blake
S.
and
Wang
X.
(
2014
)
Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population
.
J. Investig Med. Off. Publ. Am. Fed. Clin. Res.
62
,
868
874
118.
Kim
J.J.
and
Choi
Y.M.
(
2013
)
Dyslipidemia in women with polycystic ovary syndrome
.
Obstet. Gynecol. Sci.
56
,
137
142
[PubMed]
119.
Legro
R.S.
,
Kunselman
A.R.
and
Dunaif
A.
(
2001
)
Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome
.
Am. J. Med.
111
,
607
613
[PubMed]
120.
Roe
A.
,
Hillman
J.
,
Butts
S.
,
Smith
M.
,
Rader
D.
,
Playford
M.
et al.
(
2014
)
Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS
.
J. Clin. Endocrinol. Metab.
99
,
E841
E847
[PubMed]
121.
Zhou
Y.
,
Wang
X.
,
Jiang
Y.
,
Ma
H.
,
Chen
L.
,
Lai
C.
et al.
(
2017
)
Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: insights from a meta-analysis
.
Gynecol. Endocrinol.
33
,
904
910
[PubMed]
122.
Okoroh
E.M.
,
Boulet
S.L.
,
George
M.G.
and
Craig Hooper
W.
(
2015
)
Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome
.
Thromb. Res.
136
,
1165
1168
[PubMed]
123.
Indhavivadhana
S.
,
Rattanachaiyanont
M.
,
Wongwananuruk
T.
,
Techatraisak
K.
,
Rayasawath
N.
and
Dangrat
C.
(
2018
)
Endometrial neoplasia in reproductive-aged Thai women with polycystic ovary syndrome
.
Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet.
142
,
170
175
124.
Fearnley
E.J.
,
Marquart
L.
,
Spurdle
A.B.
,
Weinstein
P.
,
Webb
P.M.
,
Australian Ovarian Cancer Study Group
et al.
(
2010
)
Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study
.
Cancer Causes Control CCC
21
,
2303
2308
[PubMed]
125.
Schildkraut
J.M.
,
Schwingl
P.J.
,
Bastos
E.
,
Evanoff
A.
and
Hughes
C.
(
1996
)
Epithelial ovarian cancer risk among women with polycystic ovary syndrome
.
Obstet. Gynecol.
88
,
554
559
[PubMed]
126.
Yin
W.
,
Falconer
H.
,
Yin
L.
,
Xu
L.
and
Ye
W.
(
2019
)
Association Between Polycystic Ovary Syndrome and Cancer Risk
.
JAMA Oncol.
5
,
106
107
[PubMed]
127.
Kiddy
D.S.
,
Hamilton-Fairley
D.
,
Bush
A.
,
Short
F.
,
Anyaoku
V.
,
Reed
M.J.
et al.
(
1992
)
Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome
.
Clin. Endocrinol. (Oxf)
36
,
105
111
[PubMed]
128.
Hollmann
M.
,
Runnebaum
B.
and
Gerhard
I.
(
1996
)
Effects of weight loss on the hormonal profile in obese, infertile women
.
Hum Reprod. Oxf. Engl.
11
,
1884
1891
129.
Huber-Buchholz
M.M.
,
Carey
D.G.
and
Norman
R.J.
(
1999
)
Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone
.
J. Clin. Endocrinol. Metab.
84
,
1470
1474
[PubMed]
130.
Guzick
D.S.
,
Wing
R.
,
Smith
D.
,
Berga
S.L.
and
Winters
S.J.
(
1994
)
Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women
.
Fertil. Steril.
61
,
598
604
[PubMed]
131.
Sim
K.A.
,
Dezarnaulds
G.M.
,
Denyer
G.S.
,
Skilton
M.R.
and
Caterson
I.D.
(
2014
)
Weight loss improves reproductive outcomes in obese women undergoing fertility treatment: a randomized controlled trial
.
Clin. Obes.
4
,
61
68
[PubMed]
132.
Palomba
S.
,
Falbo
A.
,
Giallauria
F.
,
Russo
T.
,
Rocca
M.
,
Tolino
A.
et al.
(
2010
)
Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial
.
Hum Reprod. Oxf. Engl.
25
,
2783
2791
133.
Moran
L.
,
Tsagareli
V.
,
Norman
R.
and
Noakes
M.
(
2011
)
Diet and IVF pilot study: short-term weight loss improves pregnancy rates in overweight/obese women undertaking IVF
.
Aust. N. Z. J. Obstet. Gynaecol.
51
,
455
459
[PubMed]
134.
Legro
R.S.
,
Dodson
W.C.
,
Kris-Etherton
P.M.
,
Kunselman
A.R.
,
Stetter
C.M.
,
Williams
N.I.
et al.
(
2015
)
Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome
.
J. Clin. Endocrinol. Metab.
100
,
4048
4058
[PubMed]
135.
Goldman
R.H.
,
Missmer
S.A.
,
Robinson
M.K.
,
Farland
L.V.
and
Ginsburg
E.S.
(
2016
)
Reproductive outcomes differ following Roux-en-Y gastric bypass and adjustable gastric band compared with those of an obese non-surgical group
.
Obes. Surg.
26
,
2581
2589
[PubMed]
136.
Edison
E.
,
Whyte
M.
,
van Vlymen
J.
,
Jones
S.
,
Gatenby
P.
,
de Lusignan
S.
et al.
(
2016
)
Bariatric surgery in obese women of reproductive age improves conditions that underlie fertility and pregnancy outcomes: retrospective cohort study of UK National Bariatric Surgery Registry. (NBSR)
.
Obes. Surg.
26
,
2837
2842
[PubMed]
137.
Lee
R.
,
Mathew
C.J.
,
Jose
M.T.
,
Elshaikh
A.O.
,
Shah
L.
,
Cancarevic
I.
et al.
(
2020
)
A review of the impact of bariatric surgery in women with polycystic ovary syndrome
.
Cureus
12
,
e10811
[PubMed]
138.
Jamal
M.
,
Gunay
Y.
,
Capper
A.
,
Eid
A.
,
Heitshusen
D.
and
Samuel
I.
(
2012
)
Roux-en-Y gastric bypass ameliorates polycystic ovary syndrome and dramatically improves conception rates: a 9-year analysis
.
Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariatr Surg.
8
,
440
444
139.
Khazraei
H.
,
Hosseini
S.V.
,
Amini
M.
,
Bananzadeh
A.
,
Najibpour
N.
,
Ganji
F.
et al.
(
2017
)
Effect of weight loss after laparoscopic sleeve gastrectomy on infertility of women in Shiraz
.
J. Gynecol. Surg.
33
,
43
46
140.
Legro
R.S.
,
Dodson
W.C.
,
Gnatuk
C.L.
,
Estes
S.J.
,
Kunselman
A.R.
,
Meadows
J.W.
et al.
(
2012
)
Effects of gastric bypass surgery on female reproductive function
.
J. Clin. Endocrinol. Metab.
97
,
4540
4548
[PubMed]
141.
Cowan
S.
,
Lim
S.
,
Alycia
C.
,
Pirotta
S.
,
Thomson
R.
,
Gibson-Helm
M.
et al.
(
2023
)
Lifestyle management in polycystic ovary syndrome - beyond diet and physical activity
.
BMC Endocr. Disord.
23
,
14
[PubMed]
142.
Gaskins
A.J.
and
Chavarro
J.E.
(
2018
)
Diet and fertility: a review
.
Am. J. Obstet. Gynecol.
218
,
379
389
[PubMed]
143.
Kudesia
R.
,
Alexander
M.
,
Gulati
M.
,
Kennard
A.
and
Tollefson
M.
(
2021
)
Dietary approaches to women's sexual and reproductive health
.
Am. J. Lifestyle Med.
15
,
414
424
[PubMed]
144.
Panth
N.
,
Gavarkovs
A.
,
Tamez
M.
and
Mattei
J.
(
2018
)
The influence of diet on fertility and the implications for public health nutrition in the United States
.
Front Public Health
6
,
211
[PubMed]
145.
Ojeda
S.R.
,
Lomniczi
A.
and
Sandau
U.S.
(
2008
)
Glial-gonadotrophin hormone (GnRH) neurone interactions in the median eminence and the control of GnRH secretion
.
J. Neuroendocrinol.
20
,
732
742
[PubMed]
146.
Ruiz-Cruz
M.
,
Torres-Granados
C.
,
Tena-Sempere
M.
and
Roa
J.
(
2023
)
Central and peripheral mechanisms involved in the control of GnRH neuronal function by metabolic factors
.
Curr. Opin. Pharmacol.
71
,
102382
[PubMed]
147.
Marshall
J.C.
,
Dalkin
A.C.
,
Haisenleder
D.J.
,
Griffin
M.L.
and
Kelch
R.P.
(
1993
)
GnRH pulses–the regulators of human reproduction
.
Trans. Am. Clin. Climatol. Assoc.
104
,
31
46
[PubMed]
148.
Okamura
H.
,
Tsukamura
H.
,
Ohkura
S.
,
Uenoyama
Y.
,
Wakabayashi
Y.
and
Maeda
K.
(
2013
)
Kisspeptin and GnRH pulse generation
. In
Kisspeptin Signaling in Reproductive Biology
(
Kauffman
A.S.
and
Smith
J.T.
, eds), pp.
297
323
,
Springer
,
New York, NY
149.
Maeda
K.
,
Ohkura
S.
,
Uenoyama
Y.
,
Wakabayashi
Y.
,
Oka
Y.
,
Tsukamura
H.
et al.
(
2010
)
Neurobiological mechanisms underlying GnRH pulse generation by the hypothalamus
.
Brain Res.
1364
,
103
115
[PubMed]
150.
Lehman
M.N.
(
2022
)
Origins of the ‘KNDy hypothesis’ of GnRH pulse generation
.
Nat. Rev. Endocrinol.
18
,
521
521
[PubMed]
151.
Schwanzel-Fukuda
M.
,
Crossin
K.L.
,
Pfaff
D.W.
,
Bouloux
P.M.
,
Hardelin
J.P.
and
Petit
C.
(
1996
)
Migration of luteinizing hormone-releasing hormone. (LHRH) neurons in early human embryos
.
J. Comp. Neurol.
366
,
547
557
[PubMed]
152.
Bizzarri
C.
and
Cappa
M.
(
2020
)
Ontogeny of hypothalamus-pituitary gonadal axis and minipuberty: an ongoing debate?
Front Endocrinol.
11
,
187
153.
Clarkson
J.
,
Han
S.-K.
,
Liu
X.
,
Lee
K.
and
Herbison
A.E.
(
2010
)
Neurobiological mechanisms underlying kisspeptin activation of gonadotropin-releasing hormone. (GnRH) neurons at puberty
.
Mol. Cell. Endocrinol.
324
,
45
50
[PubMed]
154.
Spaziani
M.
,
Tarantino
C.
,
Tahani
N.
,
Gianfrilli
D.
,
Sbardella
E.
,
Lenzi
A.
et al.
(
2021
)
Hypothalamo-pituitary axis and puberty
.
Mol. Cell. Endocrinol.
520
,
111094
[PubMed]
155.
de Roux
N.
,
Genin
E.
,
Carel
J.-C.
,
Matsuda
F.
,
Chaussain
J.-L.
and
Milgrom
E.
(
2003
)
Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54
.
Proc. Natl. Acad. Sci. U. S. A.
100
,
10972
10976
[PubMed]
156.
Seminara
S.B.
,
Messager
S.
,
Chatzidaki
E.E.
,
Thresher
R.R.
,
Acierno
J.S.
,
Shagoury
J.K.
et al.
(
2003
)
The GPR54 gene as a regulator of puberty
.
N. Engl. J. Med.
349
,
1614
1627
[PubMed]
157.
Navarro
V.M.
,
Castellano
J.M.
,
Fernández-Fernández
R.
,
Barreiro
M.L.
,
Roa
J.
,
Sanchez-Criado
J.E.
et al.
(
2004
)
Developmental and hormonally regulated messenger ribonucleic acid expression of KiSS-1 and its putative receptor, GPR54, in rat hypothalamus and potent luteinizing hormone-releasing activity of KiSS-1 peptide
.
Endocrinology
145
,
4565
4574
[PubMed]
158.
Schally
A.V.
,
Arimura
A.
,
Kastin
A.J.
,
Matsuo
H.
,
Baba
Y.
,
Redding
T.W.
et al.
(
1971
)
Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones
.
Science
173
,
1036
1038
[PubMed]
159.
Schally
A.V.
,
Arimura
A.
,
Baba
Y.
,
Nair
R.M.
,
Matsuo
H.
,
Redding
T.W.
et al.
(
1971
)
Isolation and properties of the FSH and LH-releasing hormone
.
Biochem. Biophys. Res. Commun.
43
,
393
399
[PubMed]
160.
McNeilly
A.S.
,
Crawford
J.L.
,
Taragnat
C.
,
Nicol
L.
and
McNeilly
J.R.
(
2003
)
The differential secretion of FSH and LH: regulation through genes, feedback and packaging
.
Reprod. Camb. Engl. Suppl.
61
,
463
476
161.
Plant
T.M.
(
2015
)
The hypothalamo-pituitary-gonadal axis
.
J. Endocrinol.
226
,
T41
T54
[PubMed]
162.
Pinkerton
J.H.
,
McKay
D.G.
,
Adams
E.C.
and
Hertig
A.T.
(
1961
)
Development of the human ovary–a study using histochemical technics
.
Obstet. Gynecol.
18
,
152
181
[PubMed]
163.
Pepling
M.E.
(
2012
)
Follicular assembly: mechanisms of action
.
Reprod. Camb. Engl.
143
,
139
149
164.
O'Connell
J.M.
and
Pepling
M.E.
(
2021
)
Primordial follicle formation - some assembly required
.
Curr. Opin. Endocr. Metab. Res.
18
,
118
127
[PubMed]
165.
Baker
T.G.
(
1963
)
A quantitative and cytological study of germ cells in human ovaries
.
Proc. R. Soc. Lond. B Biol. Sci.
158
,
417
433
[PubMed]
166.
Findlay
J.K.
,
Hutt
K.J.
,
Hickey
M.
and
Anderson
R.A.
(
2015
)
How is the number of primordial follicles in the ovarian reserve established?
Biol. Reprod.
93
,
111, 1-7
[PubMed]
167.
Hansen
K.R.
,
Hodnett
G.M.
,
Knowlton
N.
and
Craig
L.B.
(
2011
)
Correlation of ovarian reserve tests with histologically determined primordial follicle number
.
Fertil. Steril.
95
,
170
175
[PubMed]
168.
Wallace
W.H.B.
and
Kelsey
T.W.
(
2010
)
Human ovarian reserve from conception to the menopause
.
PLoS ONE
5
,
e8772
[PubMed]
169.
Kelsey
T.W.
,
Anderson
R.A.
,
Wright
P.
,
Nelson
S.M.
and
Wallace
W.H.B.
(
2012
)
Data-driven assessment of the human ovarian reserve
.
Mol. Hum. Reprod.
18
,
79
87
[PubMed]
170.
Williams
C.J.
and
Erickson
G.F.
(
2000
)
Morphology and physiology of the ovary
. In
Endotext
(
Feingold
K.R.
,
Anawalt
B.
and
Blackman
M.R.
et al.
, eds),
MDText.com, Inc.
,
South Dartmouth. (MA)
171.
Allan
C.M.
,
Wang
Y.
,
Jimenez
M.
,
Marshan
B.
,
Spaliviero
J.
,
Illingworth
P.
et al.
(
2006
)
Follicle-stimulating hormone increases primordial follicle reserve in mature female hypogonadal mice
.
J. Endocrinol.
188
,
549
557
[PubMed]
172.
McGee
E.A.
,
Perlas
E.
,
LaPolt
P.S.
et al.
(
1997
)
Follicle-stimulating hormone enhances the development of preantral follicles in juvenile rats
.
Biol. Reprod.
57
,
990
998
[PubMed]
173.
Oktay
K.
,
Newton
H.
,
Mullan
J.
and
Gosden
R.G.
(
1998
)
Development of human primordial follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone
.
Hum Reprod. Oxf. Engl.
13
,
1133
1138
174.
Kishi
H.
,
Kitahara
Y.
,
Imai
F.
,
Nakao
K.
and
Suwa
H.
(
2018
)
Expression of the gonadotropin receptors during follicular development
.
Reprod. Med. Biol.
17
,
11
19
[PubMed]
175.
Rodgers
R.J.
and
Irving-Rodgers
H.F.
(
2010
)
Formation of the ovarian follicular antrum and follicular fluid
.
Biol. Reprod.
82
,
1021
1029
[PubMed]
176.
McGee
E.A.
and
Hsueh
A.J.
(
2000
)
Initial and cyclic recruitment of ovarian follicles
.
Endocr. Rev.
21
,
200
214
[PubMed]
177.
Franks
S.
(
2021
)
Androgen production and action in the ovary
.
Curr. Opin. Endocr. Metab. Res.
18
,
48
53
178.
Hillier
S.G.
,
Whitelaw
P.F.
and
Smyth
C.D.
(
1994
)
Follicular oestrogen synthesis: the “two-cell, two-gonadotrophin” model revisited
.
Mol. Cell. Endocrinol.
100
,
51
54
[PubMed]
179.
Zeleznik
A.J.
(
2004
)
The physiology of follicle selection
.
Reprod. Biol. Endocrinol. RBE
2
,
31
180.
Zeleznik
A.J.
(
1981
)
Premature elevation of systemic estradiol reduces serum levels of follicle-stimulating hormone and lengthens the follicular phase of the menstrual cycle in rhesus monkeys
.
Endocrinology
109
,
352
355
[PubMed]
181.
Strauss
J.F.
and
Williams
C.J.
(
2019
)
Chapter 8 - Ovarian Life Cycle
. In
Yen and Jaffe's Reproductive Endocrinology
Eighth Edition(
Strauss
J.F.
and
Barbieri
R.L.
, eds), pp.
167.e9
205.e9
,
Elsevier
,
Philadelphia
182.
Turathum
B.
,
Gao
E.-M.
and
Chian
R.-C.
(
2021
)
The function of cumulus cells in oocyte growth and maturation and in subsequent ovulation and fertilization
.
Cells
10
,
2292
[PubMed]
183.
Reynolds
L.P.
and
Redmer
D.A.
(
1999
)
Growth and development of the corpus luteum
.
J. Reprod. Fertil. Suppl.
54
,
181
191
[PubMed]
184.
Mlyczyńska
E.
,
Kieżun
M.
,
Kurowska
P.
,
Dawid
M.
,
Pich
K.
,
Respekta
N.
et al.
(
2022
)
New aspects of corpus luteum regulation in physiological and pathological conditions: involvement of adipokines and neuropeptides
.
Cells
11
,
957
[PubMed]
185.
Stolk
L.
,
Perry
J.R.B.
,
Chasman
D.I.
,
He
C.
,
Mangino
M.
,
Sulem
P.
et al.
(
2012
)
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways
.
Nat. Genet.
44
,
260
268
[PubMed]
186.
Pelosi
E.
,
Simonsick
E.
,
Forabosco
A.
,
Garcia-Ortiz
J.E.
and
Schlessinger
D.
(
2015
)
Dynamics of the ovarian reserve and impact of genetic and epidemiological factors on age of menopause
.
Biol. Reprod.
92
,
130, 1-9
[PubMed]
187.
Appiah
D.
,
Nwabuo
C.C.
,
Ebong
I.A.
,
Wellons
M.F.
and
Winters
S.J.
(
2021
)
Trends in age at natural menopause and reproductive life span among US women, 1959-2018
.
JAMA
325
,
1328
1330
[PubMed]
188.
Gold
E.B.
(
2011
)
The timing of the age at which natural menopause occurs
.
Obstet. Gynecol. Clin. North Am.
38
,
425
440
[PubMed]
189.
Hoyt
L.T.
and
Falconi
A.
(
2015
)
Puberty and perimenopause: reproductive transitions and their implications for women's health
.
Soc. Sci. Med. 1982
132
,
103
190.
Atwood
C.S.
,
Meethal
S.V.
,
Liu
T.
,
Wilson
A.C.
,
Gallego
M.
,
Smith
M.A.
et al.
(
2005
)
Dysregulation of the hypothalamic-pituitary-gonadal axis with menopause and andropause promotes neurodegenerative senescence
.
J. Neuropathol. Exp. Neurol.
64
,
93
103
[PubMed]
191.
Estienne
A.
,
Bongrani
A.
,
Ramé
C.
,
Kurowska
P.
,
Błaszczyk
K.
,
Rak
A.
et al.
(
2021
)
Energy sensors and reproductive hypothalamo-pituitary ovarian axis. (HPO) in female mammals: Role of mTOR. (mammalian target of rapamycin), AMPK. (AMP-activated protein kinase) and SIRT1. (Sirtuin 1)
.
Mol. Cell. Endocrinol.
521
,
111113
[PubMed]
192.
Guo
Z.
and
Yu
Q.
(
2019
)
Role of mTOR signaling in female reproduction
.
Front Endocrinol.
10
,
1
13
193.
Correia
B.
,
Sousa
M.I.
and
Ramalho-Santos
J.
(
2020
)
The mTOR pathway in reproduction: from gonadal function to developmental coordination
.
Reprod. Camb. Engl.
159
,
R173
R188
194.
Yang
W.
,
Wang
L.
,
Wang
F.
and
Yuan
S.
(
2020
)
Roles of AMP-activated protein kinase (AMPK) in mammalian reproduction
.
Front Cell Dev. Biol.
8
,
593005
[PubMed]
195.
Nguyen
T.M.D.
(
2019
)
Role of AMPK in mammals reproduction: specific controls and whole-body energy sensing
.
C. R. Biol.
342
,
1
6
[PubMed]
196.
Ruan
H.
and
Dong
L.Q.
(
2016
)
Adiponectin signaling and function in insulin target tissues
.
J. Mol. Cell Biol.
8
,
101
109
[PubMed]
197.
Saltiel
A.R.
(
2021
)
Insulin signaling in health and disease
.
J. Clin. Invest.
131
,
e142241
[PubMed]
198.
Zhang
Q.-L.
,
Wang
Y.
,
Liu
J.-S.
and
Du
Y.-Z.
(
2022
)
Effects of hypercaloric diet-induced hyperinsulinemia and hyperlipidemia on the ovarian follicular development in mice
.
J. Reprod. Dev.
68
,
173
180
[PubMed]
199.
Jeon
S.-M.
(
2016
)
Regulation and function of AMPK in physiology and diseases
.
Exp. Mol. Med.
48
,
e245
e245
[PubMed]
200.
Faber
C.L.
,
Deem
J.D.
,
Campos
C.A.
,
Taborsky
G.J.
and
Morton
G.J.
(
2020
)
CNS control of the endocrine pancreas
.
Diabetologia
63
,
2086
2094
[PubMed]
201.
Fu
Z.
,
Gilbert
E.R.
and
Liu
D.
(
2013
)
Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes
.
Curr. Diab. Rev.
9
,
25
53
202.
Melloul
D.
,
Marshak
S.
and
Cerasi
E.
(
2002
)
Regulation of insulin gene transcription
.
Diabetologia
45
,
309
326
[PubMed]
203.
Thomas
D.D.
,
Corkey
B.E.
,
Istfan
N.W.
and
Apovian
C.M.
(
2019
)
Hyperinsulinemia: an early indicator of metabolic dysfunction
.
J. Endocr. Soc.
3
,
1727
1747
[PubMed]
204.
Rostène
W.
and
De Meyts
P.
(
2021
)
Insulin: a 100-year-old discovery with a fascinating history
.
Endocr. Rev.
42
,
503
527
[PubMed]
205.
Banting
F.
and
Best
C.
(
1922
)
The internal secretion of the pancreas
.
J. Lab. Clin. Med.
7
,
251
266
206.
Cheatham
B.
and
Kahn
C.R.
(
1995
)
Insulin action and the insulin signaling network
.
Endocr. Rev.
16
,
117
142
[PubMed]
207.
Nolan
C.J.
and
Prentki
M.
(
2019
)
Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift
.
Diab. Vasc. Dis. Res.
16
,
118
127
[PubMed]
208.
Biddinger
S.B.
and
Kahn
C.R.
(
2006
)
From mice to men: Insights into the insulin resistance syndromes
.
Annu. Rev. Physiol.
68
,
123
158
[PubMed]
209.
Lei
C.
,
Wang
J.
,
Li
X.
,
Mao
Y.-Y.
and
Yan
J.-Q.
(
2023
)
Changes of insulin receptors in high fat and high glucose diet mice with insulin resistance
.
Adipocyte
12
,
2264444
[PubMed]
210.
Brüning
J.C.
,
Gautam
D.
,
Burks
D.J.
,
Gillette
J.
,
Schubert
M.
,
Orban
P.C.
et al.
(
2000
)
Role of brain insulin receptor in control of body weight and reproduction
.
Science
289
,
2122
2125
[PubMed]
211.
Brothers
K.J.
,
Wu
S.
,
DiVall
S.A.
,
Messmer
M.R.
,
Kahn
C.R.
,
Miller
R.S.
et al.
(
2010
)
Rescue of obesity-induced infertility in female mice due to a pituitary-specific knockout of the insulin receptor
.
Cell Metab.
12
,
295
305
[PubMed]
212.
Ou
X.-H.
,
Li
S.
,
Wang
Z.-B.
,
Li
M.
,
Quan
S.
,
Xing
F.
et al.
(
2012
)
Maternal insulin resistance causes oxidative stress and mitochondrial dysfunction in mouse oocytes
.
Hum Reprod. Oxf. Engl.
27
,
2130
2145
213.
Chosich
J.
,
Bradford
A.P.
,
Allshouse
A.A.
,
Reusch
J.E.B.
,
Santoro
N.
and
Schauer
I.E.
(
2017
)
Acute recapitulation of the hyperinsulinemia and hyperlipidemia characteristic of metabolic syndrome suppresses gonadotropins
.
Obes. Silver Spring Md.
25
,
553
560
214.
Wang
G.
,
Radovick
S.
,
Buckley
J.P.
,
Hauser
R.
,
Williams
P.L.
,
Hong
X.
et al.
(
2023
)
Plasma insulin concentration in newborns and children and age at menarche
.
Diabetes Care.
46
,
1231
1238
[PubMed]
215.
Park
H.T.
,
Cho
G.J.
,
Ahn
K.H.
,
Shin
J.H.
,
Kim
Y.T.
,
Hur
J.Y.
et al.
(
2010
)
Association of insulin resistance with anti‐Mullerian hormone levels in women without polycystic ovary syndrome. (PCOS)
.
Clin. Endocrinol. (Oxf)
72
,
26
31
[PubMed]
216.
Havrankova
J.
,
Roth
J.
and
Brownstein
M.
(
1978
)
Insulin receptors are widely distributed in the central nervous system of the rat
.
Nature
272
,
827
829
[PubMed]
217.
Pomytkin
I.
,
Costa-Nunes
J.P.
,
Kasatkin
V.
,
Veniaminova
E.
,
Demchenko
A.
,
Lyundup
A.
et al.
(
2018
)
Insulin receptor in the brain: mechanisms of activation and the role in the CNS pathology and treatment
.
CNS Neurosci. Ther.
24
,
763
774
[PubMed]
218.
Qiu
X.
,
Dao
H.
,
Wang
M.
,
Heston
A.
,
Garcia
K.M.
,
Sangal
A.
et al.
(
2015
)
Insulin and leptin signaling interact in the mouse Kiss1 neuron during the peripubertal period
.
PLoS ONE
10
,
e0121974
[PubMed]
219.
Evans
M.C.
,
Rizwan
M.
,
Mayer
C.
,
Boehm
U.
and
Anderson
G.M.
(
2014
)
Evidence that insulin signalling in gonadotrophin-releasing hormone and kisspeptin neurones does not play an essential role in metabolic regulation of fertility in mice
.
J. Neuroendocrinol.
26
,
468
479
[PubMed]
220.
Qiu
X.
,
Dowling
A.R.
,
Marino
J.S.
,
Faulkner
L.D.
,
Bryant
B.
,
Brüning
J.C.
et al.
(
2013
)
Delayed puberty but normal fertility in mice with selective deletion of insulin receptors from Kiss1 cells
.
Endocrinology
154
,
1337
1348
[PubMed]
221.
Navarro
V.M.
and
Kaiser
U.B.
(
2013
)
Metabolic influences on neuroendocrine regulation of reproduction
.
Curr. Opin. Endocrinol. Diab. Obes.
20
,
335
222.
Evans
M.C.
,
Hill
J.W.
and
Anderson
G.M.
(
2021
)
Role of insulin in the neuroendocrine control of reproduction
.
J. Neuroendocrinol.
33
,
e12930
[PubMed]
223.
Manaserh
I.H.
,
Chikkamenahalli
L.
,
Ravi
S.
,
Dube
P.R.
,
Park
J.J.
and
Hill
J.W.
(
2019
)
Ablating astrocyte insulin receptors leads to delayed puberty and hypogonadism in mice
.
PLoS Biol.
17
,
e3000189
[PubMed]
224.
Kim
H.H.
,
DiVall
S.A.
,
Deneau
R.M.
and
Wolfe
A.
(
2005
)
Insulin regulation of GnRH gene expression through MAP kinase signaling pathways
.
Mol. Cell. Endocrinol.
242
,
42
49
[PubMed]
225.
Adashi
E.Y.
,
Hsueh
A.J.
and
Yen
S.S.
(
1981
)
Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells
.
Endocrinology
108
,
1441
1449
[PubMed]
226.
Buggs
C.
,
Weinberg
F.
,
Kim
E.
,
Wolfe
A.
,
Radovick
S.
and
Wondisford
F.
(
2006
)
Insulin augments GnRH-stimulated LHβ gene expression by Egr-1
.
Mol. Cell. Endocrinol.
249
,
99
106
[PubMed]
227.
Salvi
R.
,
Castillo
E.
,
Voirol
M.-J.
,
Glauser
M.
,
Rey
J.-P.
,
Gaillard
R.C.
et al.
(
2006
)
Gonadotropin-releasing hormone-expressing neurons immortalized conditionally are activated by insulin: implication of the mitogen-activated protein kinase pathway
.
Endocrinology
147
,
816
826
[PubMed]
228.
DiVall
S.A.
,
Herrera
D.
,
Sklar
B.
,
Wu
S.
,
Wondisford
F.
,
Radovick
S.
et al.
(
2015
)
Insulin receptor signaling in the GnRH neuron plays a role in the abnormal GnRH pulsatility of obese female mice
.
PLoS ONE
10
,
e0119995
[PubMed]
229.
Wu
S.
,
Divall
S.
,
Nwaopara
A.
,
Radovick
S.
,
Wondisford
F.
,
Ko
C.
et al.
(
2014
)
Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell
.
Diabetes
63
,
1270
1282
[PubMed]
230.
el-Roeiy A
Chen X.
,
Roberts
V.J.
,
Shimasakai
S.
,
Ling
N.
,
LeRoith
D.
et al.
(
1994
)
Expression of the genes encoding the insulin-like growth factors. (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries
.
J. Clin. Endocrinol. Metab.
78
,
1488
1496
[PubMed]
231.
Lighten
A.D.
,
Hardy
K.
,
Winston
R.M.
and
Moore
G.E.
(
1997
)
Expression of mRNA for the insulin-like growth factors and their receptors in human preimplantation embryos
.
Mol. Reprod. Dev
47
,
134
139
[PubMed]
232.
Samoto
T.
,
Maruo
T.
,
Ladines-Llave
C.A.
,
Matsuo
H.
,
Deguchi
J.
,
Barnea
E.R.
et al.
(
1993
)
Insulin receptor expression in follicular and stromal compartments of the human ovary over the course of follicular growth, regression and atresia
.
Endocr. J.
40
,
715
726
[PubMed]
233.
Schultz
G.A.
,
Hogan
A.
,
Watson
A.J.
,
Smith
R.M.
and
Heyner
S.
(
1992
)
Insulin, insulin-like growth factors and glucose transporters: temporal patterns of gene expression in early murine and bovine embryos
.
Reprod. Fertil. Dev.
4
,
361
371
[PubMed]
234.
Acevedo
N.
,
Ding
J.
and
Smith
G.D.
(
2007
)
Insulin signaling in mouse oocytes
.
Biol. Reprod.
77
,
872
879
[PubMed]
235.
Xu
S.
,
Wu
X.
,
Dong
Y.
,
Xu
M.
,
Li
Z.
,
Chen
S.
et al.
(
2020
)
Glucose activates the primordial follicle through the AMPK/mTOR signaling pathway
.
Clin. Transl. Med.
10
,
e122
236.
Zhou
J.
,
Bievre
M.
and
Bondy
C.A.
(
2000
)
Reduced GLUT1 expression in Igf1-/- null oocytes and follicles
.
Growth Horm. IGF Res.
10
,
111
117
[PubMed]
237.
Diamanti-Kandarakis
E.
,
Argyrakopoulou
G.
,
Economou
F.
,
Kandaraki
E.
and
Koutsilieris
M.
(
2008
)
Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome. (PCOS)
.
J. Steroid Biochem. Mol. Biol.
109
,
242
246
[PubMed]
238.
Dupont
J.
and
Scaramuzzi
R.J.
(
2016
)
Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle
.
Biochem. J.
473
,
1483
1501
[PubMed]
239.
Kezele
P.R.
,
Nilsson
E.E.
and
Skinner
M.K.
(
2002
)
Insulin but not insulin-like growth factor-1 promotes the primordial to primary follicle transition
.
Mol. Cell. Endocrinol.
192
,
37
43
[PubMed]
240.
Sakaguchi
M.
,
Dominko
T.
,
Yamauchi
N.
,
Leibfried-Rutledge
M.L.
,
Nagai
T.
and
First
N.L.
(
2002
)
Possible mechanism for acceleration of meiotic progression of bovine follicular oocytes by growth factors in vitro
.
Reprod Camb. Engl.
123
,
135
142
241.
Stefanello
J.R.
,
Barreta
M.H.
,
Porciuncula
P.M.
,
Arruda
J.N.
,
Oliveira
J.F.
,
Oliveira
M.A.
et al.
(
2006
)
Effect of angiotensin II with follicle cells and insulin-like growth factor-I or insulin on bovine oocyte maturation and embryo development
.
Theriogenology
66
,
2068
2076
[PubMed]
242.
Pitetti
J.L.
,
Torre
D.
,
Conne
B.
,
Papaioannou
M.D.
,
Cederroth
C.R.
,
Xuan
S.
et al.
(
2009
)
Insulin receptor and IGF1R are not required for oocyte growth, differentiation, and maturation in mice
.
Sex. Dev Genet. Mol. Biol. Evol. Endocrinol. Embryol. Pathol. Sex Determ Differ
3
,
264
272
243.
Sekulovski
N.
,
Whorton
A.E.
,
Shi
M.
,
Hayashi
K.
and
MacLean
J.A.
(
2020
)
Periovulatory insulin signaling is essential for ovulation, granulosa cell differentiation, and female fertility
.
FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol.
34
,
2376
2391
244.
Belfiore
A.
,
Frasca
F.
,
Pandini
G.
,
Sciacca
L.
and